EMI Holding 10-K 31 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 20, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	EMMAUS LIFE SCIENCES, INC.
Entity Central Index Key	1,420,031
Document Type	10-K
Trading Symbol	EMMA
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 128,544,048
Entity Common Stock, Shares Outstanding		34,714,219
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 1,317,340	$ 472,341
Accounts receivable	14,221	101,639
Inventories, net	166,209	219,163
Investment in available-for-sale securities	10,917,301
Marketable securities, pledged to creditor	179,765	219,015
Prepaid expenses and other current assets	129,204	131,113
Total current assets	12,724,040	1,143,271
PROPERTY AND EQUIPMENT, net	53,730	58,227
OTHER ASSETS
Deposits	214,808	275,500
Total other assets	214,808	275,500
Total Assets	12,992,578	1,476,998
CURRENT LIABILITIES
Accounts payable and accrued expenses	3,201,154	4,580,494
Other current liability		88,331
Notes payable, net	4,094,429	4,656,749
Notes payable to related parties, net	1,924,850	2,766,304
Convertible notes payable, net	9,205,007	6,000,347
Convertible notes payable to related parties, net	474,000	298,000
Total current liabilities	18,899,440	18,390,225
LONG-TERM LIABILITIES
Deferred rent	57,081	59,886
Warrant derivative liabilities	10,600,000	7,863,000
Convertible notes payable, net	997,957	4,206,873
Convertible notes payable to related parties, net		320,000
Total long-term liabilities	11,655,038	12,449,759
Total Liabilities	30,554,478	30,839,984
STOCKHOLDERS' DEFICIT
Preferred stock - par value $0.001 per share, 20,000,000 shares authorized, none issued and outstanding
Common stock - par value $0.001 per share, 100,000,000 shares authorized, 34,701,219 and 28,163,478 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively	34,701	28,163
Additional paid-in capital	92,614,801	56,508,984
Accumulated other comprehensive loss	(3,450,746)	(318,324)
Accumulated deficit	(106,760,656)	(85,581,809)
Total Stockholders' Deficit	(17,561,900)	(29,362,986)
Total Liabilities & Stockholders' Deficit	$ 12,992,578	$ 1,476,998

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	20,000,000	20,000,000
Common stock, par (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	34,701,219	28,163,478
Common stock, outstanding	34,701,219	28,163,478

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
REVENUES, Net	$ 461,591	$ 590,114
COST OF GOODS SOLD	221,250	286,687
GROSS PROFIT	240,341	303,427
OPERATING EXPENSES
Research and development	1,987,966	1,579,112
Selling	438,242	428,643
General and administrative	9,342,635	10,219,683
Impairment of intangible assets		678,571
[us-gaap:OperatingExpenses]	11,768,843	12,906,009
LOSS FROM OPERATIONS	(11,528,502)	(12,602,582)
OTHER INCOME (EXPENSE)
Realized loss on securities available-for-sale		(48,709)
Gain on debt extinguishment	1,019
Loss on debt settlement	(266,736)
Gain on derecognition of accounts payable and settlement of litigation		418,366
Change in fair value of liability classified warrants		661,000
Change in fair value of warrant derivative liabilities	(2,745,890)	1,202,000
Convertible note inducement expense	(1,444,863)
Interest and other income	1,538	102,676
Interest expense	(5,191,720)	(3,227,160)
[us-gaap:NonoperatingIncomeExpense]	(9,646,652)	(891,827)
LOSS BEFORE INCOME TAXES	(21,175,154)	(13,494,409)
INCOME TAXES	3,693	3,564
NET LOSS	(21,178,847)	(13,497,973)
COMPONENTS OF OTHER COMPREHENSIVE LOSS
Unrealized holding loss on securities available-for-sale	(3,121,949)	(123,113)
Unrealized foreign currency translation effect	(10,473)	(1,196)
[us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent]	(3,132,422)	(124,309)
COMPREHENSIVE LOSS	$ (24,311,269)	$ (13,622,282)
NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.70)	$ (0.47)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (in shares)	30,194,085	28,958,580

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Dec. 31, 2014	$ 30,512	$ 51,068,677	$ (194,015)	$ (72,083,836)	$ (21,178,662)
Balance, beginning (in shares) at Dec. 31, 2014	30,511,573
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Warrants issued in conjunction with convertible note		220,071			220,071
Beneficial conversion feature related to convertible and promissory notes payable		1,388,201			1,388,201
Proceeds from exercise of warrants	$ 148	102,737			102,885
Proceeds from exercise of warrants (in shares)	148,256
Share-based compensation		3,708,801			3,708,801
Conversion of notes payable to common stock	$ 5	17,995			18,000
Conversion of notes payable to common stock (in shares)	5,898
Exercise of common stock options (cashless)	$ 2	(2)
Exercise of common stock options (cashless) (in shares)	2,000
Stock cancelled	$ (2,504)	2,504
Stock cancelled (in shares)	(2,504,249)
Unrealized loss on marketable securities, net of tax			(123,113)		(123,113)
Foreign currency translation effect			(1,196)		(1,196)
Net loss				(13,497,973)	(13,497,973)
Balance, ending at Dec. 31, 2015	$ 28,163	56,508,984	(318,324)	(85,581,809)	(29,362,986)
Balance, ending (in shares) at Dec. 31, 2015	28,163,478
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Warrants issued in conjunction with convertible note		644,550			644,550
Beneficial conversion feature related to convertible and promissory notes payable		3,463,281			3,463,281
Stock issued for cash	$ 5,125	22,336,031			22,341,156
Stock issued for cash (in shares)	5,124,702
Share-based compensation		3,328,400			3,328,400
Conversion of notes payable to common stock	$ 1,397	4,888,708			4,890,105
Conversion of notes payable to common stock (in shares)	1,397,173
Convertible note inducement		1,444,863			1,444,863
Exercise of common stock options (cashless)	$ 16	(16)
Exercise of common stock options (cashless) (in shares)	15,866
Unrealized loss on marketable securities, net of tax			(3,121,949)		(3,121,949)
Foreign currency translation effect			(10,473)		(10,473)
Net loss				(21,178,847)	(21,178,847)
Balance, ending at Dec. 31, 2016	$ 34,701	$ 92,614,801	$ (3,450,746)	$ (106,760,656)	$ (17,561,900)
Balance, ending (in shares) at Dec. 31, 2016	34,701,219

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (21,178,847)	$ (13,497,973)
Adjustments to reconcile net loss to net cash flows used in operating activities
Depreciation and amortization	15,198	233,179
Impairment of intangible assets		678,571
Interest expense accrued from discount of convertible notes	3,132,857	1,597,064
Foreign exchange adjustments on convertible notes and notes payable	57,563	474
Realized loss on marketable securities available-for-sale		48,709
Gain/Loss on debt extinguishment	(1,019)
Gain/Loss on debt settlement	266,736
Gain on settlement of litigation		(418,366)
Share-based compensation	3,328,400	3,708,801
Convertible Note Inducement Expense	1,444,863
Change in fair value of liability classified warrants		(661,000)
Change in fair value of warrant derivative liabilities	2,745,890	(1,202,000)
Net changes in operating assets and liabilities
Accounts receivable	92,590	(58,904)
Inventories	52,287	31,251
Prepaid expenses and other current assets	(3,400)	(1,559)
Deposits	61,557	30,879
Accounts payable and accrued expenses	43,672	2,407,203
Other current liability	(88,331)	88,331
Deferred rent	(2,929)	56,157
Net cash flows used in operating activities	(10,032,913)	(6,959,183)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sales of investment securities available-for-sale	(14,000,000)	46,728
Purchases of property and equipment	(10,369)	(4,731)
Net cash flows from (used in) investing activities	(14,010,369)	41,997
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable issued	2,754,700	4,235,566
Proceeds from convertible notes payable issued	4,640,904	3,024,558
Payments of notes payable	(3,639,971)	(250,000)
Payments of convertible notes payable	(1,202,852)	(279,800)
Proceeds from exercise of warrants		102,885
Proceeds from issuance of common stock	22,341,156
Net cash flows from financing activities	24,893,937	6,833,209
Effect of exchange rate changes on cash	(5,656)
Net increase (decrease) in cash and cash equivalents	844,999	(83,977)
Cash and cash equivalents, beginning of period	472,341	556,318
Cash and cash equivalents, end of period	1,317,340	472,341
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid	683,038	319,282
Income taxes paid	3,693	3,364
Conversion of notes payable to common stock	4,600,931	$ 18,000
Conversion of accrued interest payable to common stock	$ 289,175

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1—DESCRIPTION OF BUSINESS Organization Emmaus Medical is a Delaware corporation originally incorporated on September 12, 2003. Emmaus Medical, LLC was organized on December 20, 2000. In October 2003, Emmaus Medical, LLC conducted a reorganization and merged with Emmaus Medical. As a result of the merger, Emmaus Medical acquired the exclusive patent rights for a treatment for sickle cell disease ("SCD"). In October 2010, the Company established Emmaus Medical Japan, Inc., a Japanese corporation ("EM Japan") by funding 97% of the initial capital. EM Japan is engaged in the business of trading in nutritional supplements and other medical products and drugs. The results of EM Japan have been included in the consolidated financial statements of the Company since the date of formation. The aggregate formation cost was $52,500. Emmaus Medical acquired the additional 3% of the outstanding shares of EM Japan during the three months ended March 31, 2011 and is now the 100% owner of the outstanding share capital. In November 2011, the Company formed Emmaus Medical Europe, Ltd. ("EM Europe"), a wholly owned subsidiary of Emmaus Medical. EM Europe's primary focus is expanding the business of Emmaus Medical in Europe. In December 2016, the Company formed Emmaus Life Sciences Korea Co. Ltd. ("ELSK"), a wholly owned subsidiary of Emmaus Medical. ELSK's primary focus is expanding the business of Emmaus Medical in Korea. Emmaus, its wholly-owned subsidiary, Emmaus Medical, and Emmaus Medical's wholly-owned subsidiaries, Newfield Nutrition Corporation ("Newfield Nutrition"), EM Japan, ELSK and EM Europe, are collectively referred to herein as the "Company." Nature of Business To a lesser extent, the Company is also engaged in the marketing and sale of NutreStore®, which has received approval from the U.S. Food and Drug Administration ("FDA"), as a treatment for short bowel syndrome ("SBS") in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication. The Company's indirect wholly-owned subsidiary, Newfield Nutrition, sells L- glutamine as a nutritional supplement under the brand name AminoPure® through retail stores in multiple states in the United States and via importers and distributors in Japan, Taiwan and South Korea. The Company also owns a minority interest of less than 1% in CellSeed, Inc., a Japanese company listed on the Tokyo Stock Exchange ("CellSeed"), which is engaged in research and development of regenerative medicine products and the manufacture and sale of temperature- responsive cell culture equipment. The Company also is involved in research focused on providing innovative solutions for tissue-engineering through the development of novel cell harvest methods and three-dimensional living tissue replacement products for "cell sheet therapy" and regenerative medicine and the future commercialization of such products. Immaterial corrections of prior year amounts As previously disclosed in the Company's Quarterly Report on Form 10-Q for the periods ended September 30, 2015 and June 30, 2015, on April 28, 2015, Dr. Yutaka Niihara, the Company's President, Chief Executive Officer and Chairman of the Board, filed a complaint in the Court of Chancery of the State of Delaware under Section 225 of the Delaware General Corporation Law against Tracey C. Doi, Henry A. McKinnell, Jr., Akiko M. Miyashita, Phillip M. Satow and Mayuran Sriskandarajah, each of whom was a member of the Board as of April 24, 2015 ("Incumbant Directors"), Sarissa Capital Management L.P. ("Sarissa") and T.R. Winston & Company, LLC ("TRW"), as defendants, and the Company as nominal defendant. Among other things, the lawsuit sought an order to void any actions taken by Incumbent Directors since April 24, 2015 and an order for maintaining the company status quo during pendency of the suit. On June 10, 2015, the Delaware court issued a Status Quo Order until conclusion of the lawsuit. On November 19, 2015, Sarissa, Niihara and Emmaus entered a three-party settlement agreement that provided Sarissa or its designee would be paid $800,000. The agreement was signed by "Yutaka Niihara, M.D., M.P.H.", and it was made in connection with an agreement entitled "Amendment No. 1 to Agreement" also executed on November 19,2015. The Amendment No. 1 to Agreement terminated a September 11, 2013 agreement among Emmaus, Niihara, Winston and Sarissa. On November 19, 2015, Niihara, Sarissa and Emmaus filed a joint stipulation to dismiss the lawsuit filed April 24, 2015 against Sarissa. By stipulation, the September 11, 2013 agreement among Emmaus, Niihara, Winston and Sarissa was terminated. The November 19, 2015 settlement agreement and the amount of $800,000 was not recorded as a liability and legal settlement expense by the Company for the year ended December 31, 2015. The primary reason for this lack of accounting recognition is due to a misunderstanding by the Company of this matter at the time of filing 2015 Form 10-K that the settlement entered did not involve the Company and was of personal matter in nature for Dr. Yutaka Niihara. However, upon further examination of this matter on or about November 2016, it was then determined by management, board of directors and concurred by the Company’s outside legal counsel that Dr. Yutaka Niihara was in fact acting as an agent of the Company and thus the settlement amount should have been accounted for by the Company for the year ended December 31, 2015. Accordingly, on November 17, 2016, the Board of Directors of Emmaus unanimously approved that for the legal conflict with Sarissa in 2015, Niihara was acting as an agent for Emmaus and that the related, incurred settlement expenses would be paid by Emmaus. A reconciliation of the effects of the adjustments to the previously reported consolidated balance sheet at December 31, 2015 follows: As Previously Reported Adjustment As Revised As of December 31, 2015 Accounts payable and accrued expenses 3,780,494 800,000 4,580,494 Total current liabilities 17,590,225 800,000 18,390,225 Total liabilities 30,039,984 800,000 30,839,984 Accumulated deficit (84,781,809 ) (800,000 ) (85,581,809 ) Total stockholders' deficit (28,562,986 ) (800,000 ) (29,362,986 ) A reconciliation of the effect of the adjustments to the previously reported consolidated statement of comprehensive loss for the year ended December 31, 2015 follows: As Previously Reported Adjustment As Revised General and administrative 9,419,683 800,000 10,219,683 Loss from operations (11,802,582 ) (800,000 ) (12,602,582 ) Loss before income taxes (12,694,409 ) (800,000 ) (13,494,409 ) A reconciliation of the effect of the adjustments to the previously reported consolidated statement of cash flows for the year ended December 31, 2015 follows: As Previously Reported Adjustment As Revised Net loss (12,697,973 ) (800,000 ) (13,497,973 ) Accounts payable and accrued expenses 1,607,203 800,000 2,407,203

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation Going concern Principles of consolidation Estimates The warrants issued by the Company in a private placement in September 2013 and replacement warrants issued in June 2014 contain non-standard anti- dilution protection and, consequently, are being accounted for as liabilities that are remeasured to fair market value at each reporting period (Note 6). In addition, the remaining initial private placement warrants may now utilize a cashless exercise feature since the shares associated with them were not registered by the one-year anniversary of their issue. These warrants have now been reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. The initial value as well as the fair value of all such warrants were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. Actual results could differ from those estimates. Cash and cash equivalents Inventories All of the raw material purchases during the year ended December 31, 2016 and 2015 was from one vendor. The below table presents inventory by category: December 31, Inventory by category 2016 2015 Raw materials and components $ — $ — Work-in-process 34,462 45,355 Finished goods 131,747 173,808 Total $ 166,209 $ 219,163 Prepaid expenses and other current assets December 31, 2016 December 31, 2015 Prepaid insurance $ 100,060 $ 97,708 Other prepaid expenses and current assets 29,144 33,405 $ 129,204 $ 131,113 Deposits Revenue recognition With prior written approval of the Company, in certain situations, product is returnable only by its direct customers for a returned goods credit, for product that is expired, damaged in transit, or which is discontinued, withdrawn or recalled. The Company estimates its sales returns based upon its prior sales and return history and accrues a sales return allowance at the time of sale. Historically, sales returns have been immaterial. The Company pays royalties on an annual basis based on existing license arrangements. These royalties are recognized as cost of goods sold upon sale of the products. Allowance for doubtful accounts Advertising cost Property and equipment Intangibles Impairment of long-lived assets If the Company determines that the carrying values of long-lived assets may not be recoverable based upon the existence of one or more indicators of impairment, the Company performs an undiscounted cash flow analysis to determine if impairment exists. If impairment exists, the Company measures the impairment based on the difference between the asset's carrying amount and its fair value, and the impairment is charged to the consolidated statement of comprehensive loss in the period in which the long-lived asset impairment is determined to have occurred. The Company has determined that an impairment of the carrying value of its long-lived assets existed at December 31, 2015 and no impairment existed at December 31, 2016. Research and development Share-based compensation Income taxes For balance sheet presentation, current deferred tax assets and liabilities within each tax jurisdiction have been offset and presented as a single amount and non-current deferred tax assets and liabilities within each tax jurisdiction have been offset and presented as a single amount. When tax returns are filed, it is highly probable that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more- likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits along with any associated interest and penalties that would be payable to the taxing authorities upon examination. As of December 31, 2016, the Company had no unrecognized tax benefits, and the Company had no positions which, in the opinion of management, would be reversed if challenged by a taxing authority. In the event the Company is assessed interest and/or penalties, such amounts will be classified as income tax expense in the financial statements. As of December 31, 2016, all federal tax returns since 2013 and state tax returns since 2012 are still subject to adjustment upon audit. No tax returns are currently being examined by taxing authorities. Comprehensive income (loss) Marketable securities As of December 31, 2016, 39,250 shares of CellSeed stock are pledged to secure a $300,000 convertible note issued to Mitsubishi UFJ Capital III Limited Partnership that is due on demand and are classified as current assets, as marketable securities, pledged to creditor. Gain on derecognition of accounts payable and settlement of litigation Foreign Currency Translation Financial Instruments Fair value measurements Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 inputs must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value assigned to marketable securities is determined by obtaining quoted prices on nationally recognized securities exchanges, and are classified as Level 1 investments at December 31, 2016 and 2015. The fair value of the Company's debt instruments is not materially different from their carrying values as presented. The fair value of the Company's convertible debt instruments was determined based on Level 2 inputs. The carrying value of the debt was discounted based on allocating proceeds to other financial instruments within the arrangement as discussed in Note 5. The Company issued stock purchase warrants in conjunction with its September 2013 private placement and issued replacement warrants upon the exercise of certain of such warrants in June 2014 (see Note 1 and Note 6). Such warrants and replacement warrants contain non-standard anti-dilution protection, and consequently, are accounted for as liabilities measured at fair value on a recurring basis, whose fair value is determined using Level 3 inputs. In addition, the remaining initial private placement warrants may now utilize a cashless exercise feature since the shares associated with them were not registered by the one-year anniversary of their issue. These warrants have now been reclassified from liability classified warrants to warrant derivative liabilities and continue to be remeasured at fair value each reporting period. The Level 3 inputs in the valuation of warrants include expected term and expected volatility. The following tables present the activity for those items measured at fair value on a recurring basis using Level 3 inputs during 2016 and 2015: Year ended December 31, Liability Classified Warrants—Stock Purchase Warrants 2016 2015 Balance, beginning of period $ — $ 3,206,000 Fair value at issuance date — — Settlement of liability associated with warrants exercised — — Reclassification to warrant derivative liabilities — (2,545,000 ) Reduction of the warrants exercised to intrinsic value included in the statement of comprehensive loss — — Change in fair value included in the statement of comprehensive loss — (661,000 ) ​ ​ ​ ​ ​ ​ ​ ​ Balance, end of period $ — $ — Year ended December 31, Warrant Derivative Liabilities—Stock Purchase Warrants 2016 2015 Balance, beginning of period $ 7,863,000 $ 6,520,000 Reclassification from liability classified warrants — 2,545,000 Change in fair value included in the statement of comprehensive loss 2,737,000 (1,202,000 ) ​ ​ ​ ​ ​ ​ ​ ​ Balance, end of period $ 10,600,000 $ 7,863,000 The value of the liability classified warrants , the value of warrant derivative liability and the change in fair value of the liability classified warrants and warrant derivative liability were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. The values as of December 31, 2016, December 31, 2015, December 31, 2014, December 31, 2013, and the initial value as of September 11, 2013 were calculated based on the following assumptions: December 31, 2016 December 31, 2015 December 31, 2014 December 31, 2013 Initial Value Stock price $ 6.00 $ 4.70 $ 4.90 $ 3.60 $ 3.60 Risk-free interest rate 1.09 % 1.23 % 1.38 % 1.75 % 1.72 % Expected volatility (peer group) 68.30 % 64.10 % 71.50 % 63.20 % 72.40 % Expected life (in years) 1.70 2.70 3.70 4.70 5.00 Expected dividend yield — — — — — Number outstanding 3,320,501 3,320,501 3,320,501 3,320,501 3,320,501 Balance, end of period: Liability classified warrants $ — $ — $ 3,206,000 $ 6,517,000 $ 7,541,000 Warrant derivative liabilities $ 10,600,000 $ 7,863,000 $ 6,520,000 $ — $ — Debt and Related Party Debt Debt with Conversion and Other Options Type of Loan Term of Loan Stated Annual Interest Rate Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2015 convertible notes payable Due on demand ~ 2 years 10 % $ 4,051,022 $3.05 ~ $4.50 $ 1,388,201 110,417 $ 4.90 $ 220,071 14% ~ 109% 2016 convertible notes payable Due on demand ~ 2 years 10 % 10,866,291 $3.50 ~ $4.50 3,196,544 75,000 $ 4.70 161,658 14% ~ 102% 2016 promissory notes payable 11.5 ~ 12.5 months 10 % 1,295,000 — — 118,750 $ 4.50 474,002 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 16,212,313 $ 4,584,745 304,167 $ 855,731 Related party notes are disclosed as separate line items in the Company's balance sheet presentation. Net loss per share "Earnings per Share, Recent accounting pronouncements Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. In January 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3—PROPERTY AND EQUIPMENT Property and equipment consisted of the following at: December 31, 2016 December 31, 2015 Equipment $ 175,410 $ 164,931 Leasehold improvements 30,804 30,579 Furniture and fixtures 74,760 74,682 280,974 270,192 Less: accumulated depreciation (227,244 ) (211,965 ) Total $ 53,730 $ 58,227 During the years ended December 31, 2016 and 2015, depreciation expense was $15,279 and $18,893, respectively.

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 4—ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following at: December 31, 2016 December 31, 2015 Accounts payable Clinical and regulatory expenses $ 145,239 $ 322,193 Legal expenses 43,700 242,384 Consulting fees 99,800 74,700 Accounting fees 65,267 230,598 Selling expenses 60,724 34,279 Investor relations and public relations expenses 19,931 18,097 Other vendors 41,640 318,269 Total accounts payable 476,301 1,240,520 Accrued interest payable, related parties 274,851 176,940 Accrued interest payable 1,441,450 1,586,472 Accrued expenses 716,886 1,284,896 Deferred salary 291,666 291,666 Total accounts payable and accrued expenses $ 3,201,154 $ 4,580,494

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 5—NOTES PAYABLE Notes payable consisted of the following at December 31, 2016 and 2015: Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding December 31, 2016 Discount Amount December 31, 2016 Carrying Amount December 31 2016 Shares Underlying Notes December 31, 2016 Principal Outstanding December 31, 2015 Discount Amount December 31, 2015 Carrying Amount December 31, 2015 Shares Underlying Notes December 31, 2015 Notes payable 2013 10% Due on demand — 2014 11% Due on demand ~ 2 years — — — — — 1,446,950 — 1,446,950 — 2015 11% Due on demand — 2,406,194 — 2,406,194 — 2,379,799 — 2,379,799 — 2016 11% Due on demand — 833,335 — 833,335 — — — — — $ 4,094,429 — $ 4,094,429 — $ 4,656,749 $ — $ 4,656,749 — Current $ 4,094,429 $ — $ 4,094,429 — $ 4,656,749 $ — $ 4,656,749 — Long-term $ — $ — $ — — $ — $ — $ — — Notes payable—related party 2012 8% Due on demand — 2013 8% Due on demand — 50,000 — 50,000 — 50,000 — 50,000 — 2014 11% Due on demand ~ 2 years — — — — — 240,308 — 240,308 — 2015 10% ~ 11% Due on demand — 514,340 — 514,340 — 1,849,266 — 1,849,266 — 2016 10% ~ 11% Due on demand — 860,510 — 860,510 — — — — — $ 1,924,850 $ — $ 1,924,850 — $ 2,766,304 $ — $ 2,766,304 — Current $ 1,924,850 $ — $ 1,924,850 — $ 2,766,304 $ — $ 2,766,304 — Long-term $ — $ — $ — — $ — $ — $ — — Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding December 31, 2016 Discount Amount December 31, 2016 Carrying Amount December 31 2016 Shares Underlying Notes December 31, 2016 Principal Outstanding December 31, 2015 Discount Amount December 31, 2015 Carrying Amount December 31, 2015 Shares Underlying Notes December 31, 2015 Convertible notes payable 2010 6% 5 years $3.05 2011 10% 5 years $3.05 300,000 — 300,000 98,285 500,000 — 500,000 163,809 2013 10% 2 years $3.60 — — — — 525,257 — 525,257 185,553 2014 10% Due on demand ~ 2 years $3.05 ~$3.60 452,168 — 452,168 152,986 4,378,563 353,700 4,024,863 1,120,470 2015 10% 2 years $3.50 ~$3.60 2,904,800 104,389 2,800,411 889,115 5,681,166 526,066 5,155,100 1,517,996 2016 10% Due on demand ~ 1 year $3.50 ~$4.50 8,126,129 1,475,744 6,650,385 2,193,687 — — — — $ 11,783,097 $ 1,580,133 $ 10,202,964 3,334,073 $ 11,086,986 $ 879,766 $ 10,207,220 2,988,484 Current $ 10,499,303 $ 1,294,296 $ 9,205,007 2,984,161 $ 6,358,698 $ 358,351 $ 6,000,347 1,762,849 Long-term $ 1,283,794 $ 285,837 $ 997,957 349,912 $ 4,728,288 $ 521,415 $ 4,206,873 1,225,635 Convertible notes payable—related party 2012 10% Due on demand $3.30 2015 10% 2 years $4.50 220,000 — 220,000 54,463 320,000 — 320,000 72,354 $ 474,000 $ — $ 474,000 148,995 $ 618,000 $ — $ 618,000 180,859 Current $ 474,000 $ — $ 474,000 148,995 $ 298,000 $ — $ 298,000 108,505 Long-term $ — $ — $ — — $ 320,000 $ — $ 320,000 72,354 Grand Total $ 18,276,376 $ 1,580,133 $ 16,696,243 3,483,068 $ 19,128,039 $ 879,766 $ 18,248,273 3,169,343 The average stated interest rate of notes payable for the years ended December 31, 2016 and 2015 was 10% in each period. The average effective interest rate of notes payable for the years ended December 31, 2016 and 2015 was 27% and 23% respectively, after giving effect to discounts relating to beneficial conversion features and the fair value of warrants issued in connection with these notes. The notes payable and convertible notes payable do not have restrictive financial covenants or acceleration clauses associated with a material adverse change event. The holders of the convertible notes have the option to convert their notes into the Company's common stock at the stated conversion price during the term of their convertible notes. Conversion prices on these convertible notes payable range from $3.05 to $3.60 per share. Certain notes with a $4.50 and a $7.00 stated conversion price in the second year of their two-year term are subject to automatic conversion into shares of the Company's common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering. All due on demand notes are treated as current liabilities. Contractual principal payments due on notes payable are as follows: Year Ending at December 31, 2016 2017 $ 16,992,582 2018 1,283,794 Total $ 18,276,376 The Company estimated the total fair value of any beneficial conversion feature and accompanying warrants in allocating the debt proceeds. The proceeds allocated to the beneficial conversion feature were determined by taking the estimated fair value of shares issuable under the convertible notes less the fair value of the number of shares that would be issued if the conversion rate equaled the fair value of the Company's common stock as of the date of issuance (see Note 2). The fair value of the warrants issued in conjunction with notes was determined using the Black-Scholes-Merton option pricing model with the following inputs for the years ended: 2016 2015 Stock price $5.00 $4.50 Exercise price $4.50 - 4.70 $4.90 Term 5 years 5 years Risk-free interest rate 1.01 - 1.28% 1.57% Expected dividend yield — — Expected volatility 65.4 - 69.6% 67.3% In situations where the debt included both a beneficial conversion feature and a warrant, the proceeds were allocated to the warrants and beneficial conversion feature based on the pro-rata fair value.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 6—STOCKHOLDERS' DEFICIT Private Placement The warrants issued in the Private Placement and the Broker Warrants entitle the holders thereof to purchase, at any time on or prior to September 11, 2018, shares of common stock of the Company at an exercise price of $3.50 per share. The warrants contain non-standard anti-dilution protection and, consequently, are being accounted for as liabilities, were originally recorded at fair value, and are adjusted to fair market value each reporting period. Because the shares of common stock underlying the Private Placement warrants and Broker Warrants were not effectively registered for resale by September 11, 2014, the warrant holders have an option to exercise the warrants using a cashless exercise feature. The shares have not been registered for resale as of December 31, 2016. The availability to warrant holders of the cashless exercise feature as of September 11, 2014 caused the then-outstanding 2,225,036 Private Placement warrants and Broker Warrants with fair value of $7,068,000 to be reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. On June 10, 2014, certain warrant holders exercised 1,095,465 warrants issued in the Private Placement for the exercise price of $3.50 per share, resulting in the Company receiving aggregate exercise proceeds of $3.8 million and issuing 1,095,465 shares of common stock. Prior to exercise, these Private Placement warrants were accounted for at fair value as liability classified warrants. As of June 10, 2014, immediately prior to exercise, the carrying value of these Private Placement warrants was reduced to their fair value immediately prior to exercise of $1.8 million, representing their intrinsic value, with this adjusted carrying value of $1.8 million being transferred to additional paid-in capital. Also on June 10, 2014, based on an offer made to holders of Private Placement warrants in connection with such exercises, the Company issued an aggregate of 1,095,465 replacement warrants to holders exercising Private Placement warrants, which replacement warrants have terms that are generally the same as the exercised warrants, including an expiration date of September 11, 2018 and an exercise price of $3.50 per share. The replacement warrants are treated for accounting purposes as liability classified warrants, and their issuance gave rise to a $3.5 million warrant exercise inducement expense based on their fair value as of issuance as determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. Because the shares of common stock underlying the replacement warrants were not effectively registered for resale by June 10, 2015, the warrant holders have an option to exercise the warrants using a cashless exercise feature. The shares have not been registered for resale as of December 31, 2016. The availability to warrant holders of the cashless exercise feature as of June 10, 2015 caused the then-outstanding 1,095,465 replacement warrants with fair value of $2,545,000 to be reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. As of December 31, 2016 and 2015, the aggregate fair value of the Private Placement warrants, replacement warrants, and the Broker Warrants were $10,600,000 and $7,863,000, respectively (see Note 2). For further details regarding registration rights associated with the Private Placement warrants, replacement warrants, and Broker Warrants, see the Registration Rights section below in this footnote. A summary of outstanding warrants as of December 31, 2016 and 2015 is presented below. Year ended December 31, 2016 Year ended December 31, 2015 Warrants outstanding, beginning of period 3,530,918 5,101,450 Granted 1,493,750 110,417 Exercised — (148,256 ) Cancelled, forfeited and expired — (1,532,693 ) Warrants outstanding, end of period 5,024,668 3,530,918 ​ ​ ​ ​ ​ ​ ​ ​ A summary of outstanding warrants by year issued and exercise price as of December 31, 2016 is presented below. Outstanding Weighted Average Remaining Contractual Life (Years) Exercisable Exercise Price Number of Warrants Issued Weighted Average Exercise Price Total Weighted Average Exercise Price At December 31, 2013 $3.30 50,000 1.33 $ 3.30 50,000 $ 3.30 $3.50 2,225,036 1.70 $ 3.50 2,225,036 $ 3.50 2013 total 2,275,036 2,275,036 At December 31, 2014 $3.50 1,145,465 1.72 $ 3.50 1,145,465 $ 3.50 2014 total 1,145,465 1,145,465 At December 31, 2015 $4.90 110,417 3.18 $ 4.90 110,417 $ 4.90 2015 total 110,417 110,417 During 2016 $4.50 118,750 4.50 $ 4.50 118,750 $ 4.50 $4.70 75,000 4.33 $ 4.70 75,000 $ 4.70 $5.00 1,300,000 4.36 $ 5.00 1,300,000 $ 5.00 Total 5,024,668 5,024,668 Stock options Management has valued stock options at their date of grant utilizing the Black-Scholes-Merton Option pricing model. The fair value of the underlying shares was determined by the market value of stock of similar companies and recent arm's length transactions involving the sale of the Company's common stock. The expected volatility was calculated using the historical volatility of a similar public entity in the industry through August 2013 and a group of similar public entities thereafter. The following table presents the assumptions used on recent dates on which options were granted by the Board of Directors. May 10, 2016 January 14, 2016 Stock price $ 5.00 $ 4.70 Exercise price $ 5.00 $ 4.70 Term 10 years 10 years Risk-Free Interest Rate 1.36 % 1.70 % Dividend Yield 0.00 % 0.00 % Volatility 65.55 % 64.14 % In making the determination of fair value and finding similar companies, the Company considered the industry, stage of life cycle, size and financial leverage of such other entities. While the Company was initially able to identify only one similar public company using these criteria, based on the more advanced stage of development of the Company additional similar companies with enough historical data that met the industry criterion have now been identified. Accordingly, the Company has based its expected volatility on the historical stock prices of a group peer of companies since September 2013. The risk-free interest rate is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options depending on the date of the grant and expected life of the options. During the year ended December 31, 2016, the Company's Board of Directors granted 2,596,200 options to its officers, directors and employees. Of these options, 300,000 granted to its directors will vest in equal one-third installments on each of the first three anniversaries of the grant date, have an exercise price of $4.70 per share and are exercisable through 2026. The remaining 2,296,200 options will vest as follows: one-third (1/3) will vest on the first anniversary of the grant date, and the remaining two-thirds (2/3) will vest in twenty-four approximately equal monthly installments over a period of two years thereafter, except for 300,000 options granted to its directors which will vest in equal one-third installments over three years starting May 10, 2017. These options have an exercise price of $5.00 per share and are exercisable through 2026. During the year ended December 31, 2015, no options were granted by the Company's Board of Directors. As of December 31, 2016, there were 6,955,200 options outstanding under the 2011 Stock Incentive Plan. A summary of the Company's stock option activity for the years ended December 31, 2016 and 2015 is presented below. December 31, 2016 December 31, 2015 Number of Options Weighted- Average Exercise Price Number of Options Weighted- Average Exercise Price Options outstanding, beginning of period 4,753,335 $ 3.60 5,669,000 $ 3.68 Granted or deemed issued 2,596,200 $ 4.97 — — Exercised (15,866 ) $ 3.60 (2,000 ) $ 3.60 Cancelled, forfeited and expired (378,469 ) $ 3.91 (913,665 ) $ 4.05 Options outstanding, end of period 6,955,200 $ 4.10 4,753,335 $ 3.60 Options exercisable at end of year 4,372,667 $ 3.59 4,379,335 $ 3.60 Options available for future grant 2,044,800 4,246,665 During the years ended December 31, 2016 and 2015, the Company recognized $3.3 million and $3.7 million, respectively, of share-based compensation cost arising from stock option grants. As of December 31, 2016, there was $8.0 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2011 Stock Incentive Plan. That cost is expected to be recognized over the weighted average remaining period of 2.1 years. Registration rights If the shares of common stock underlying these warrants to purchase 3,320,501 shares are not registered for resale at the time of exercise, and the registration rights described above then apply with respect to the holder of such warrants, such holder may exercise such warrants on a cashless basis. In such a cashless exercise of all the shares covered by the warrant, the warrant holder would receive a number of shares equal to the quotient of (i) the difference between the fair market value of the common stock, as defined, and the $3.50 exercise price, as adjusted, multiplied by the number of shares exercisable under the warrant, divided by (ii) the fair market value of the common stock, as defined. As of December 31, 2016, based on a fair market value of a share of Company common stock of $6.00 and 3,320,501 warrants issued and outstanding and eligible for cashless exercise, the maximum number of shares the Company would be required to issue, if the warrant holders elected to exercise the cashless exercise feature with respect to all then eligible warrants, is 1,383,542 shares. If the fair market value of a share of Company common stock were to increase by $1.00 from $6.00 to $7.00, the maximum number of shares the Company would be required to issue, if the warrant holders elected to exercise the cashless exercise feature with respect to all then eligible warrants, would increase to 1,660,251 shares as of December 31, 2016. The Company has not yet filed a registration statement with respect to the resale of the Registrable Securities The Company believes that it has used commercially reasonable efforts to file a registration statement with respect to the resale of Registrable Securities. Korean Private Placement On September 29, 2016, KPM and Hanil purchased and acquired from the Company 3,777,778 shares and 666,667 shares, respectively, of common stock at a price of $4.50 a share for $17 million and $3 million, respectively, for a gross total of $20 million. The Company recognized $720,000 as a reduction to its additional paid-in-capital for fees and commissions payable by the Company in connection with the transaction. Pursuant to the terms of the Letter of Agreement dated September 12, 2016, the Company invested $13 million and $1 million in capital increases by KPM and Hanil, respectively, at $15.32 and $3.68, respectively, per capita share. Pursuant to the terms of a subscription agreement dated as of September 11, 2013 among the Company and certain purchasers of shares of our common stock and warrants to purchase shares of our common stock, the purchasers are entitled to participation rights with respect to the sale of shares pursuant to the Letter of Agreement. To the extent the purchasers exercise their participation rights, we may be obliged to sell to them a specified number of shares of our common stock at the price per share and other terms set forth in the Letter of Agreement. There can be no assurance that any purchaser will exercise its participation rights or that any shares of our common stock will be issued to any purchaser. On August 26, 2016, the Company offered all note holders an opportunity to convert all or a portion of the principal amount of and accrued interest on their notes into shares of Company common stock at a price of $3.50 per share. Pursuant to the offer, 19 note holders elected to convert a total of $4,007,598 of principal and $260,124 of accrued interest on their notes. The conversion price of $3.50 per share was less than the stated conversion price of the convertible notes that were converted, which conversion prices ranged from $4.50 to $7.00 per share. Accordingly, the conversion resulted in the Company recognizing an inducement expense of $1,444,863, which represents the fair value of the incremental increase in the number of shares of Company common stock received by the convertible note holders. The note holders of a total of $622,384 of principal and accrued interest on non-convertible notes participated in the offer. Under the guidance of ASC 405-20, the Company de-recognized the principal and accrued interest on these non-convertible notes in consideration for issuing Company common stock. As a result of delivering its common stock to the holders of these non-convertible notes holders, the Company concluded that it has satisfied and is released from its legal obligation for the notes. The fair value of the common stock provided as consideration was $889,120 whereas the face value of the principal and accrued interest was $622,384, resulting in a loss on the debt settlement of $266,736 charged in full against the earning during the year ended December 31, 2016.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7—INCOME TAXES The provision for income taxes consists of the following for the years ended December 31: 2016 2015 Current U.S. $ 2,400 $ 2,400 International 1,293 1,164 Deferred U.S. — — International — — $ 3,693 $ 3,564 A valuation allowance for the net deferred tax assets has been recorded as it is more likely than not that these benefits will not be realized through future operations. Deferred tax assets consist of the following as of December 31, 2016 and 2015: 2016 2015 Net operating loss carryforward $ 20,881,231 $ 16,650,797 General business tax credit 7,504,146 6,510,162 Stock options 7,633,468 6,271,690 Charitable contribution 56,617 79,944 Accrued expenses 384,690 290,083 Other 412,630 444,929 Total gross deferred tax assets 36,872,782 30,247,605 Less valuation allowance (36,740,418 ) (30,116,742 ) Net deferred tax assets $ 132,364 $ 130,863 Deferred tax liabilities consist of the following as of December 31, 2016 and 2015: 2016 2015 Unrealized gain on foreign exchange translation and others $ (83,880 ) $ (99,228 ) Unrealized gain on securities available-for-sale (48,484 ) (31,635 ) Total deferred tax liability $ (132,364 ) $ (130,863 ) During 2016 and 2015, the valuation allowance increased by $6,623,676 and $4,932,738, respectively. As of December 31, 2016 and 2015, the Company had net operating loss carryforwards for federal reporting purposes of approximately $51,240,000 and $42,909,000, which are available to offset future federal taxable income, if any, through 2036. In addition, the Company had net operating loss carryforwards for state income tax purposes of approximately $49,561,000 and $40,440,000 respectively, which expire in various years through 2036. The utilization of our net operating losses could be subject to an annual limitation as a result of certain past and future events, such as acquisition or other significant equity events, which may be deemed as a "change in ownership" under the provisions of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitations could result in the expiration of net operating losses and tax credits before utilization. As of December 31, 2016 and 2015, the Company has general business tax credits of $7,504,000 and $6,510,000, respectively, for federal tax purposes. The tax credits are available to offset future tax liabilities, if any, through 2026. The income tax provision differs from that computed using the statutory federal tax rate of 34%, due to the following: 2016 2015 Tax benefit at statutory federal rate $ (7,481,009 ) $ (4,295,120 ) State taxes, net of federal tax benefit (695,697 ) (469,692 ) Increase in valuation allowance 6,640,524 4,948,921 Permanent items 3,633,702 675,959 General business tax credit (993,983 ) (789,556 ) Other (1,099,844 ) (66,948 ) $ 3,693 $ 3,564 As of December 31, 2016 and 2015, the Company had no unrecognized tax benefits, and the Company had no positions which, in the opinion of management, would be reversed if challenged by a taxing authority. In the event the Company is assessed interest and/or penalties, such amounts will be classified as income tax expense in the financial statements. As of December 31, 2016, all federal tax returns since 2013 and state tax returns since 2012 are still subject to adjustment upon audit. No tax returns are currently being examined by taxing authorities.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8—COMMITMENTS AND CONTINGENCIES Distribution contract Operating leases Future minimum lease payments under the agreements are as follows: Year Amount 2017 553,956 2018 538,498 2019 126,115 Total $ 1,218,569

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9—RELATED PARTY TRANSACTIONS The following table sets forth information relating to the Company's loans from related persons outstanding as of December 31, 2016. Class Lender Annual Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2016 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes at December 31, 2016 Notes payable to related parties—current: Hope Hospice(1) 8 % 1/17/2012 Due on demand $ 200,000 $ 200,000 $ — $ 20,000 $ — — Hope Hospice(1) 8 % 6/14/2012 Due on demand 200,000 200,000 — 20,000 — — Hope Hospice(1) 8 % 6/21/2012 Due on demand 100,000 100,000 — 10,000 — — Hope Hospice(1) 8 % 2/11/2013 Due on demand 50,000 50,000 — 5,000 — — Hope Hospice(1) 10 % 1/7/2015 Due on demand 100,000 100,000 — — — — Lan T. Tran(2) 10 % 2/9/2015 Due on demand 10,000 10,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum(2) 10 % 2/20/2015 Due on demand 10,000 10,000 — — — — Yutaka Niihara(2)(3) 10 % 5/21/2015 Due on demand 94,340 826,105 731,765 47,822 — — Masaharu & Emiko Osato(3) 11 % 12/29/2015 Due on demand 300,000 300,000 — — — — Lan T. Tran(2) 11 % 2/10/2016 Due on demand 130,510 130,510 — — — — Hideki & Eiko Uehara(4) 11 % 2/15/2016 Due on demand — 133,333 133,333 12,226 3.50 — Masaharu & Emiko Osato(3) 11 % 2/25/2016 Due on demand 400,000 400,000 — — — — Hope Hospice(1) 10 % 4/4/2016 Due on demand 50,000 50,000 — — — — Willis C. Lee(2)(3) 10 % 4/8/2016 Due on demand — 79,700 79,700 1,288 — — Lan T. Tran(2) 10 % 4/29/2016 Due on demand 20,000 20,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum(2) 10 % 5/5/2016 Due on demand 10,000 10,000 — — — — Hope Hospice(1) 10 % 6/3/2016 Due on demand 250,000 250,000 — — — — Sub total $ 1,924,850 $ 2,869,648 $ 944,798 $ 116,336 $ — — Convertible notes payable to related parties—current: Yasushi Nagasaki(2) 10 % 6/29/2012 Due on demand $ 254,000 $ 388,800 $ 134,800 $ 27,824 $ 3.30 94,532 Charles & Kimxa Stark(2) 10 % 10/1/2015 2 years 20,000 20,000 — — 4.50 5,002 Yutaka & Soomi Niihara(2)(3) 10 % 11/16/2015 2 years 200,000 200,000 — — 4.50 49,461 Sub total $ 474,000 $ 608,800 $ 134,800 $ 27,824 — 148,995 Total $ 2,398,850 $ 3,478,448 $ 1,079,598 $ 144,160 — 148,995 (1) Dr. Niihara, who is the Company's CEO, is also the CEO of Hope Hospice. (2) Officer (3) Director (4) Family of Officer/Director The following table sets forth information relating to the Company's loans from related persons outstanding as of December 31, 2015. Class Lender Annual Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2015 Highest Principal Outstanding Amount of Principal Repaid Amount of Interest Paid Conversion Rate Shares Underlying Notes at December 31, 2015 Notes payable to related parties—current: Hope Hospice(1) 8 % 1/17/2012 Due on demand $ 200,000 $ 200,000 $ — $ 8,000 $ — — Hope Hospice(1) 8 % 6/14/2012 Due on demand 200,000 200,000 — 8,000 — — Hope Hospice(1) 8 % 6/21/2012 Due on demand 100,000 100,000 — 4,000 — — Yutaka Niihara(2)(4) 10 % 12/5/2012 Due on demand 126,729 1,213,700 1,086,970 56,722 — — Hope Hospice(1) 8 % 2/11/2013 Due on demand 50,000 50,000 — 2,000 — — Lan T. Tran(2) 11 % 2/10/2014 Due on demand 106,976 106,976 — — — — Hideki & Eiko Uehara(5) 11 % 2/15/2014 2 years 133,333 133,333 — — — — Hope Hospice(1) 10 % 1/7/2015 Due on demand 100,000 100,000 — — — — James Lee(5) 10 % 1/26/2015 Due on demand 50,000 50,000 — — — — Hope Hospice(1) 10 % 1/29/2015 Due on demand 30,000 30,000 — — — — Yutaka Niihara(2)(4) 10 % 1/29/2015 Due on demand — 20,000 20,000 773 Lan T. Tran(2) 10 % 2/9/2015 Due on demand 10,000 10,000 — — — — Charles Stark(2) 10 % 2/10/2015 Due on demand 10,000 10,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum(2) 10 % 2/20/2015 Due on demand 10,000 10,000 — — — — Cuc T. Tran(5) 11 % 3/5/2015 1 year 13,161 13,161 — — — — Yutaka Niihara(2)(4) 10 % 4/7/2015 Due on demand 500,000 500,000 — — — — Yutaka Niihara(2)(4) 10 % 5/21/2015 Due on demand 826,105 826,105 — — — — Masaharu & Emiko Osato(4) 11 % 12/29/2015 Due on demand 300,000 300,000 — — — — Sub total $ 2,766,304 $ 3,873,275 $ 1,106,970 $ 79,495 $ — — Convertible notes payable to related parties—current: Yasushi Nagasaki(2) 10 % 6/29/2012 Due on demand $ 298,000 $ 388,800 $ 90,800 $ — $ 3.30 108,505 Sub total $ 298,000 $ 388,800 $ 90,800 $ — $ — 108,505 Non-Current, convertible notes payable to related parties: Yutaka Niihara(2)(4) 10 % 9/29/2015 2 years $ 100,000 $ 100,000 $ — $ — $ 4.50 22,794 Charles & Kimxa Stark(2) 10 % 10/1/2015 2 years 20,000 20,000 — — 4.50 4,556 Yutaka & Soomi Niihara(2)(4) 10 % 11/16/2015 2 years 200,000 200,000 4.50 45,004 Sub total 320,000 320,000 $ — $ — $ — 72,354 Total $ 3,384,304 $ 4,582,075 $ 1,197,770 $ 79,495 $ — 180,859 (1) Dr. Niihara is the Chief Executive Officer of Hope Hospice. (2) Officer. (3) Director. (4) Family of officer or director. Litigation with AFH Advisory L-glutamine Therapy for SCD and Thalassemia Patent License

GEOGRAPHIC INFORMATION

GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION	NOTE 10—GEOGRAPHIC INFORMATION For the years ended December 31, 2016 and 2015, the Company earned revenue from countries outside of the United States as outlined in the table below. Country Revenue for the year ended December 31, 2016 % of Total Revenue year ended December 31, 2016 Revenue for the year ended December 31, 2015 % of Total Revenue year ended December 31, 2015 Japan $ 160,543 35 % $ 194,142 33 % Taiwan 220,397 48 % 277,637 47 % South Korea — 0 % 39,660 7 % The Company did not have any significant currency translation or foreign transaction adjustments during the years ended December 31, 2016 and 2015.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11—SUBSEQUENT EVENTS Subsequent to the year ended December 31, 2016, the Company issued the following: Notes Issued after December 31, 2016 Principal Amounts Annual Interest Rate Term of Notes Conversion Price Convertible notes(1) $ 504,312 10 % Due on Demand to 2 Years $ 3.60 Convertible notes(1) 1,130,536 10 % 6 Months to 2 Years $ 3.50 Convertible note 200,000 10 % Due on Demand to 6 Months $ 7.60 Promissory note(1)(2) 605,315 11 % Due on Demand Promissory notes—related party(1) 12,000 10 % Due on Demand — Total $ 2,452,163 (1) Refinancings of prior notes already outstanding. (2) Principal amount of note is JPY68,320,000 which was converted into US dollars using an exchange rate of 0.008860 as of February 17, 2017. Subsequent to December 31, 2016, the Company issued 13,000 shares of common stock for gross proceeds of $98,000. As previously reported, on January 16, 2017, the Company entered into a letter of intent ("LOI") with Generex Biotechnology Corporation ("Generex") which contemplates that Generex will acquire a controlling interest in the Company for a total consideration of $225,000,000, payable $10,000,000 in cash and $215,000,000 in shares of Generex's common stock, which the Company refers to as the "Generex shares." The Generex shares are to be valued for this purpose at $3.80 per share, subject to adjustment in certain events. Under the LOI, Generex paid the Company $500,000 as a deposit for an initial cash consideration and was to pay the Company another deposit of $1,500,000 by February 6, 2017. On February 6, 2017, the Company granted Generex an extension of the payment date to February 16, 2017 and, by a letter amendment dated February 16, 2017, the Company granted Generex another extension of the payment date to February 24, 2017 and otherwise amended the LOI. On March 3, 2017, Generex and the Company further amended the LOI to provide as follows: • Generex agreed to pay the Company an additional deposit of $500,000 on or prior to March 6, 2017, which the Company has received. • Within ten trading days after March 14, 2017, the date of effectiveness of a reverse stock split of Generex common stock, Generex must pay the Company another deposit of $3,000,000, which the Company has received. • The parties will use their best efforts to negotiate and sign a definitive purchase agreement no later than March 30, 2017. • The remaining $6,000,000 of the cash consideration will be paid to the Company at the closing under a definitive purchase agreement, which is to occur no later than five trading days after the date Generex amends its certificate of incorporation to effect an increase in its authorized capital, but no later than May 1, 2017. • The closing of the proposed acquisition by Generex is to occur no later than May 8, 2017. • If a definitive purchase agreement is not executed or the closing does not occur by the required deadlines, and the LOI is terminated by either party, the Company will refund and return to Generex all deposits within 60 days after the termination. In consideration for the foregoing waivers, extensions and amendments, Generex has agreed to issue to the Company 24,414,063 of restricted shares of Generex common stock within three trading days after Generex effects the planned increase in its authorized capital. The parties' respective obligations under the LOI to consummate the proposed acquisition are subject to a number of conditions, including completion of due diligence to each party's satisfaction parties and the negotiation and execution of a definitive purchase agreement, and there is no assurance these conditions will be satisfied. Any definitive purchase agreement also would contain customary conditions to closing, which may or may not be satisfied or waived by the parties. Although the Company has no present intention to terminate the LOI or to abandon the proposed acquisition, the Company may choose to do so if the conditions to the proposed acquisition have not been satisfied by the required deadlines, unless such deadlines are extended. If one or more of the conditions are not satisfied, the Company may decide to abandon the proposed acquisition if the board of directors determines that it is in the best interests of the Company to do so. For all of the foregoing reasons, there is no assurance that the proposed acquisition by Generex and the payment to the Company of the cash consideration and the Generex shares will be completed on time, or at all, and the discussions in the Annual Report assume that the proposed acquisition will not be completed. If the proposed acquisition by Generex is completed, the Company's capitalization, the risks related to its common stock and other information in the Annual Report would change materially from the descriptions in this Annual Report.

SUMMARY OF SIGNIFICANT ACCOUN18

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation
Going concern	Going concern
Principles of consolidation	Principles of consolidation
Estimates	Estimates The warrants issued by the Company in a private placement in September 2013 and replacement warrants issued in June 2014 contain non-standard anti- dilution protection and, consequently, are being accounted for as liabilities that are remeasured to fair market value at each reporting period (Note 6). In addition, the remaining initial private placement warrants may now utilize a cashless exercise feature since the shares associated with them were not registered by the one-year anniversary of their issue. These warrants have now been reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. The initial value as well as the fair value of all such warrants were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents—Cash and cash equivalents include short-term securities with original maturities of less than ninety days. The Company maintains its cash and cash equivalents at insured financial institutions, the balances of which may, at times, exceed federally insured limits. Management believes that the risk of loss due to the concentrations is minimal.
Inventories	Inventories All of the raw material purchases during the year ended December 31, 2016 and 2015 was from one vendor. The below table presents inventory by category: December 31, Inventory by category 2016 2015 Raw materials and components $ — $ — Work-in-process 34,462 45,355 Finished goods 131,747 173,808 ​ ​ ​ ​ ​ ​ ​ ​ Total $ 166,209 $ 219,163 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Prepaid expenses and other current assets	Prepaid expenses and other current assets December 31, 2016 December 31, 2015 Prepaid insurance $ 100,060 $ 97,708 Other prepaid expenses and current assets 29,144 33,405 ​ ​ ​ ​ ​ ​ ​ ​ $ 129,204 $ 131,113
Deposits	Deposits
Revenue recognition	Revenue recognition With prior written approval of the Company, in certain situations, product is returnable only by its direct customers for a returned goods credit, for product that is expired, damaged in transit, or which is discontinued, withdrawn or recalled. The Company estimates its sales returns based upon its prior sales and return history and accrues a sales return allowance at the time of sale. Historically, sales returns have been immaterial. The Company pays royalties on an annual basis based on existing license arrangements. These royalties are recognized as cost of goods sold upon sale of the products.
Allowance for doubtful accounts	Allowance for doubtful accounts
Advertising cost	Advertising cost
Property and equipment	Property and equipment
Intangibles	Intangibles
Impairment of long-lived assets	Impairment of long-lived assets If the Company determines that the carrying values of long-lived assets may not be recoverable based upon the existence of one or more indicators of impairment, the Company performs an undiscounted cash flow analysis to determine if impairment exists. If impairment exists, the Company measures the impairment based on the difference between the asset's carrying amount and its fair value, and the impairment is charged to the consolidated statement of comprehensive loss in the period in which the long-lived asset impairment is determined to have occurred. The Company has determined that an impairment of the carrying value of its long-lived assets existed at December 31, 2015 and no impairment existed at December 31, 2016.
Research and development	Research and development
Share-based compensation	Share-based compensation
Income taxes	Income taxes For balance sheet presentation, current deferred tax assets and liabilities within each tax jurisdiction have been offset and presented as a single amount and non-current deferred tax assets and liabilities within each tax jurisdiction have been offset and presented as a single amount. When tax returns are filed, it is highly probable that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more- likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits along with any associated interest and penalties that would be payable to the taxing authorities upon examination. As of December 31, 2016, the Company had no unrecognized tax benefits, and the Company had no positions which, in the opinion of management, would be reversed if challenged by a taxing authority. In the event the Company is assessed interest and/or penalties, such amounts will be classified as income tax expense in the financial statements. As of December 31, 2016, all federal tax returns since 2013 and state tax returns since 2012 are still subject to adjustment upon audit. No tax returns are currently being examined by taxing authorities.
Comprehensive income (loss)	Comprehensive income (loss)
Marketable securities	Marketable securities As of December 31, 2016, 39,250 shares of CellSeed stock are pledged to secure a $300,000 convertible note issued to Mitsubishi UFJ Capital III Limited Partnership that is due on demand and are classified as current assets, as marketable securities, pledged to creditor.
Gain on derecognition of accounts payable and settlement of litigation	Gain on derecognition of accounts payable and settlement of litigation
Foreign Currency Translation	Foreign Currency Translation
Financial Instruments	Financial Instruments
Fair value measurements	Fair value measurements Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 inputs must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value assigned to marketable securities is determined by obtaining quoted prices on nationally recognized securities exchanges, and are classified as Level 1 investments at December 31, 2016 and 2015. The fair value of the Company's debt instruments is not materially different from their carrying values as presented. The fair value of the Company's convertible debt instruments was determined based on Level 2 inputs. The carrying value of the debt was discounted based on allocating proceeds to other financial instruments within the arrangement as discussed in Note 5. The Company issued stock purchase warrants in conjunction with its September 2013 private placement and issued replacement warrants upon the exercise of certain of such warrants in June 2014 (see Note 1 and Note 6). Such warrants and replacement warrants contain non-standard anti-dilution protection, and consequently, are accounted for as liabilities measured at fair value on a recurring basis, whose fair value is determined using Level 3 inputs. In addition, the remaining initial private placement warrants may now utilize a cashless exercise feature since the shares associated with them were not registered by the one-year anniversary of their issue. These warrants have now been reclassified from liability classified warrants to warrant derivative liabilities and continue to be remeasured at fair value each reporting period. The Level 3 inputs in the valuation of warrants include expected term and expected volatility. The following tables present the activity for those items measured at fair value on a recurring basis using Level 3 inputs during 2016 and 2015: Year ended December 31, Liability Classified Warrants—Stock Purchase Warrants 2016 2015 Balance, beginning of period $ — $ 3,206,000 Fair value at issuance date — — Settlement of liability associated with warrants exercised — — Reclassification to warrant derivative liabilities — (2,545,000 ) Reduction of the warrants exercised to intrinsic value included in the statement of comprehensive loss — — Change in fair value included in the statement of comprehensive loss — (661,000 ) ​ ​ ​ ​ ​ ​ ​ ​ Balance, end of period $ — $ — Year ended December 31, Warrant Derivative Liabilities—Stock Purchase Warrants 2016 2015 Balance, beginning of period $ 7,863,000 $ 6,520,000 Reclassification from liability classified warrants — 2,545,000 Change in fair value included in the statement of comprehensive loss 2,737,000 (1,202,000 ) ​ ​ ​ ​ ​ ​ ​ ​ Balance, end of period $ 10,600,000 $ 7,863,000 The value of the liability classified warrants , the value of warrant derivative liability and the change in fair value of the liability classified warrants and warrant derivative liability were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. The values as of December 31, 2016, December 31, 2015, December 31, 2014, December 31, 2013, and the initial value as of September 11, 2013 were calculated based on the following assumptions: December 31, 2016 December 31, 2015 December 31, 2014 December 31, 2013 Initial Value Stock price $ 6.00 $ 4.70 $ 4.90 $ 3.60 $ 3.60 Risk-free interest rate 1.09 % 1.23 % 1.38 % 1.75 % 1.72 % Expected volatility (peer group) 68.30 % 64.10 % 71.50 % 63.20 % 72.40 % Expected life (in years) 1.70 2.70 3.70 4.70 5.00 Expected dividend yield — — — — — Number outstanding 3,320,501 3,320,501 3,320,501 3,320,501 3,320,501 Balance, end of period: Liability classified warrants $ — $ — $ 3,206,000 $ 6,517,000 $ 7,541,000 Warrant derivative liabilities $ 10,600,000 $ 7,863,000 $ 6,520,000 $ — $ —
Debt and Related Party Debt	Debt and Related Party Debt Debt with Conversion and Other Options Type of Loan Term of Loan Stated Annual Interest Rate Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2015 convertible notes payable Due on demand ~ 2 years 10 % $ 4,051,022 $3.05 ~ $4.50 $ 1,388,201 110,417 $ 4.90 $ 220,071 14% ~ 109% 2016 convertible notes payable Due on demand ~ 2 years 10 % 10,866,291 $3.50 ~ $4.50 3,196,544 75,000 $ 4.70 161,658 14% ~ 102% 2016 promissory notes payable 11.5 ~ 12.5 months 10 % 1,295,000 — — 118,750 $ 4.50 474,002 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 16,212,313 $ 4,584,745 304,167 $ 855,731 Related party notes are disclosed as separate line items in the Company's balance sheet presentation.
Net loss per share	Net loss per share "Earnings per Share,
Recent accounting pronouncements	Recent accounting pronouncements Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. In January 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business

DESCRIPTION OF BUSINESS (Tables

DESCRIPTION OF BUSINESS (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of reconciliation of the effects of the adjustments to the previously reported balance sheet	A reconciliation of the effects of the adjustments to the previously reported consolidated balance sheet at December 31, 2015 follows: As Previously Reported Adjustment As Revised As of December 31, 2015 Accounts payable and accrued expenses 3,780,494 800,000 4,580,494 Total current liabilities 17,590,225 800,000 18,390,225 Total liabilities 30,039,984 800,000 30,839,984 Accumulated deficit (84,781,809 ) (800,000 ) (85,581,809 ) Total stockholders' deficit (28,562,986 ) (800,000 ) (29,362,986 )
Schedule of reconciliation of the effect of the adjustments to the previously reported statement of operations	A reconciliation of the effect of the adjustments to the previously reported consolidated statement of comprehensive loss for the year ended December 31, 2015 follows: As Previously Reported Adjustment As Revised General and administrative 9,419,683 800,000 10,219,683 Loss from operations (11,802,582 ) (800,000 ) (12,602,582 ) Loss before income taxes (12,694,409 ) (800,000 ) (13,494,409 )
Schedule of A reconciliation of the effect of the adjustments to the previously reported statement of cash flows	A reconciliation of the effect of the adjustments to the previously reported consolidated statement of cash flows for the year ended December 31, 2015 follows: As Previously Reported Adjustment As Revised Net loss (12,697,973 ) (800,000 ) (13,497,973 ) Accounts payable and accrued expenses 1,607,203 800,000 2,407,203

SUMMARY OF SIGNIFICANT ACCOUN20

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of inventory	All of the raw material purchases during the year ended December 31, 2016 and 2015 was from one vendor. The below table presents inventory by category: December 31, Inventory by category 2016 2015 Raw materials and components $ — $ — Work-in-process 34,462 45,355 Finished goods 131,747 173,808 ​ ​ ​ ​ ​ ​ ​ ​ Total $ 166,209 $ 219,163 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets December 31, 2016 December 31, 2015 Prepaid insurance $ 100,060 $ 97,708 Other prepaid expenses and current assets 29,144 33,405 ​ ​ ​ ​ ​ ​ ​ ​ $ 129,204 $ 131,113 ​
Schedule of changes in fair value of Level 3 liabilities	The following tables present the activity for those items measured at fair value on a recurring basis using Level 3 inputs during 2016 and 2015: Year ended December 31, Liability Classified Warrants—Stock Purchase Warrants 2016 2015 Balance, beginning of period $ — $ 3,206,000 Fair value at issuance date — — Settlement of liability associated with warrants exercised — — Reclassification to warrant derivative liabilities — (2,545,000 ) Reduction of the warrants exercised to intrinsic value included in the statement of comprehensive loss — — Change in fair value included in the statement of comprehensive loss — (661,000 ) ​ ​ ​ ​ ​ ​ ​ ​ Balance, end of period $ — $ — Year ended December 31, Warrant Derivative Liabilities—Stock Purchase Warrants 2016 2015 Balance, beginning of period $ 7,863,000 $ 6,520,000 Reclassification from liability classified warrants — 2,545,000 Change in fair value included in the statement of comprehensive loss 2,737,000 (1,202,000 ) ​ ​ ​ ​ ​ ​ ​ ​ Balance, end of period $ 10,600,000 $ 7,863,000
Schedule of assumptions used in the valuation of warrants	The values as of December 31, 2016, December 31, 2015, December 31, 2014, December 31, 2013, and the initial value as of September 11, 2013 were calculated based on the following assumptions: December 31, 2016 December 31, 2015 December 31, 2014 December 31, 2013 Initial Value Stock price $ 6.00 $ 4.70 $ 4.90 $ 3.60 $ 3.60 Risk-free interest rate 1.09 % 1.23 % 1.38 % 1.75 % 1.72 % Expected volatility (peer group) 68.30 % 64.10 % 71.50 % 63.20 % 72.40 % Expected life (in years) 1.70 2.70 3.70 4.70 5.00 Expected dividend yield — — — — — Number outstanding 3,320,501 3,320,501 3,320,501 3,320,501 3,320,501 Balance, end of period: Liability classified warrants $ — $ — $ 3,206,000 $ 6,517,000 $ 7,541,000 Warrant derivative liabilities $ 10,600,000 $ 7,863,000 $ 6,520,000 $ — $ —
Schedule of notes payable with beneficial conversion feature or warrants attached	The following table presents the effective interest rates on the original loan principal amount for loans originated in the respective periods that either had a beneficial conversion interest or an attached warrant: Type of Loan Term of Loan Stated Annual Interest Rate Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2015 convertible notes payable Due on demand ~ 2 years 10 % $ 4,051,022 $3.05 ~ $4.50 $ 1,388,201 110,417 $ 4.90 $ 220,071 14% ~ 109% 2016 convertible notes payable Due on demand ~ 2 years 10 % 10,866,291 $3.50 ~ $4.50 3,196,544 75,000 $ 4.70 161,658 14% ~ 102% 2016 promissory notes payable 11.5 ~ 12.5 months 10 % 1,295,000 — — 118,750 $ 4.50 474,002 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 16,212,313 $ 4,584,745 304,167 $ 855,731

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment consisted of the following at: December 31, 2016 December 31, 2015 Equipment $ 175,410 $ 164,931 Leasehold improvements 30,804 30,579 Furniture and fixtures 74,760 74,682 280,974 270,192 Less: accumulated depreciation (227,244 ) (211,965 ) Total $ 53,730 $ 58,227

ACCOUNTS PAYABLE AND ACCRUED 22

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued expenses	Accounts payable and accrued expenses consisted of the following at: December 31, 2016 December 31, 2015 Accounts payable Clinical and regulatory expenses $ 145,239 $ 322,193 Legal expenses 43,700 242,384 Consulting fees 99,800 74,700 Accounting fees 65,267 230,598 Selling expenses 60,724 34,279 Investor relations and public relations expenses 19,931 18,097 Other vendors 41,640 318,269 ​ ​ ​ ​ ​ ​ ​ ​ Total accounts payable 476,301 1,240,520 ​ ​ ​ ​ ​ ​ ​ ​ Accrued interest payable, related parties 274,851 176,940 Accrued interest payable 1,441,450 1,586,472 Accrued expenses 716,886 1,284,896 Deferred salary 291,666 291,666 ​ ​ ​ ​ ​ ​ ​ ​ Total accounts payable and accrued expenses $ 3,201,154 $ 4,580,494 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ F-20

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of notes payable	Notes payable consisted of the following at December 31, 2016 and 2015: Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding December 31, 2016 Discount Amount December 31, 2016 Carrying Amount December 31 2016 Shares Underlying Notes December 31, 2016 Principal Outstanding December 31, 2015 Discount Amount December 31, 2015 Carrying Amount December 31, 2015 Shares Underlying Notes December 31, 2015 Notes payable 2013 10% Due on demand — 2014 11% Due on demand ~ 2 years — — — — — 1,446,950 — 1,446,950 — 2015 11% Due on demand — 2,406,194 — 2,406,194 — 2,379,799 — 2,379,799 — 2016 11% Due on demand — 833,335 — 833,335 — — — — — $ 4,094,429 — $ 4,094,429 — $ 4,656,749 $ — $ 4,656,749 — Current $ 4,094,429 $ — $ 4,094,429 — $ 4,656,749 $ — $ 4,656,749 — Long-term $ — $ — $ — — $ — $ — $ — — Notes payable—related party 2012 8% Due on demand — 2013 8% Due on demand — 50,000 — 50,000 — 50,000 — 50,000 — 2014 11% Due on demand ~ 2 years — — — — — 240,308 — 240,308 — 2015 10% ~ 11% Due on demand — 514,340 — 514,340 — 1,849,266 — 1,849,266 — 2016 10% ~ 11% Due on demand — 860,510 — 860,510 — — — — — $ 1,924,850 $ — $ 1,924,850 — $ 2,766,304 $ — $ 2,766,304 — Current $ 1,924,850 $ — $ 1,924,850 — $ 2,766,304 $ — $ 2,766,304 — Long-term $ — $ — $ — — $ — $ — $ — — Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding December 31, 2016 Discount Amount December 31, 2016 Carrying Amount December 31 2016 Shares Underlying Notes December 31, 2016 Principal Outstanding December 31, 2015 Discount Amount December 31, 2015 Carrying Amount December 31, 2015 Shares Underlying Notes December 31, 2015 Convertible notes payable 2010 6% 5 years $3.05 2011 10% 5 years $3.05 300,000 — 300,000 98,285 500,000 — 500,000 163,809 2013 10% 2 years $3.60 — — — — 525,257 — 525,257 185,553 2014 10% Due on demand ~ 2 years $3.05 ~$3.60 452,168 — 452,168 152,986 4,378,563 353,700 4,024,863 1,120,470 2015 10% 2 years $3.50 ~$3.60 2,904,800 104,389 2,800,411 889,115 5,681,166 526,066 5,155,100 1,517,996 2016 10% Due on demand ~ 1 year $3.50 ~$4.50 8,126,129 1,475,744 6,650,385 2,193,687 — — — — $ 11,783,097 $ 1,580,133 $ 10,202,964 3,334,073 $ 11,086,986 $ 879,766 $ 10,207,220 2,988,484 Current $ 10,499,303 $ 1,294,296 $ 9,205,007 2,984,161 $ 6,358,698 $ 358,351 $ 6,000,347 1,762,849 Long-term $ 1,283,794 $ 285,837 $ 997,957 349,912 $ 4,728,288 $ 521,415 $ 4,206,873 1,225,635 Convertible notes payable—related party 2012 10% Due on demand $3.30 2015 10% 2 years $4.50 220,000 — 220,000 54,463 320,000 — 320,000 72,354 $ 474,000 $ — $ 474,000 148,995 $ 618,000 $ — $ 618,000 180,859 Current $ 474,000 $ — $ 474,000 148,995 $ 298,000 $ — $ 298,000 108,505 Long-term $ — $ — $ — — $ 320,000 $ — $ 320,000 72,354 Grand Total $ 18,276,376 $ 1,580,133 $ 16,696,243 3,483,068 $ 19,128,039 $ 879,766 $ 18,248,273 3,169,343
Schedule of contractual principal payments of notes payable	Contractual principal payments due on notes payable are as follows: Year Ending at December 31, 2016 2017 $ 16,992,582 2018 1,283,794 Total $ 18,276,376
Schedule of fair value assumptions for warrants issued in conjunction with notes	The fair value of the warrants issued in conjunction with notes was determined using the Black-Scholes-Merton option pricing model with the following inputs for the years ended: 2016 2015 Stock price $5.00 $4.50 Exercise price $4.50 - 4.70 $4.90 Term 5 years 5 years Risk-free interest rate 1.01 - 1.28% 1.57% Expected dividend yield — — Expected volatility 65.4 - 69.6% 67.3%

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of outstanding warrants	A summary of outstanding warrants as of December 31, 2016 and 2015 is presented below. Year ended December 31, 2016 Year ended December 31, 2015 Warrants outstanding, beginning of period 3,530,918 5,101,450 Granted 1,493,750 110,417 Exercised — (148,256 ) Cancelled, forfeited and expired — (1,532,693 ) Warrants outstanding, end of period 5,024,668 3,530,918
Schedule of outstanding warrants by year issued and exercise price	A summary of outstanding warrants by year issued and exercise price as of December 31, 2016 is presented below. Outstanding Weighted Average Remaining Contractual Life (Years) Exercisable Exercise Price Number of Warrants Issued Weighted Average Exercise Price Total Weighted Average Exercise Price At December 31, 2013 $3.30 50,000 1.33 $ 3.30 50,000 $ 3.30 $3.50 2,225,036 1.70 $ 3.50 2,225,036 $ 3.50 2013 total 2,275,036 2,275,036 At December 31, 2014 $3.50 1,145,465 1.72 $ 3.50 1,145,465 $ 3.50 2014 total 1,145,465 1,145,465 At December 31, 2015 $4.90 110,417 3.18 $ 4.90 110,417 $ 4.90 2015 total 110,417 110,417 During 2016 $4.50 118,750 4.50 $ 4.50 118,750 $ 4.50 $4.70 75,000 4.33 $ 4.70 75,000 $ 4.70 $5.00 1,300,000 4.36 $ 5.00 1,300,000 $ 5.00 Total 5,024,668 5,024,668
Schedule of valuation assumptions	Management has valued stock options at their date of grant utilizing the Black-Scholes-Merton Option pricing model. The fair value of the underlying shares was determined by the market value of stock of similar companies and recent arm's length transactions involving the sale of the Company's common stock. The expected volatility was calculated using the historical volatility of a similar public entity in the industry through August 2013 and a group of similar public entities thereafter. The following table presents the assumptions used on recent dates on which options were granted by the Board of Directors. May 10, 2016 January 14, 2016 Stock price $ 5.00 $ 4.70 Exercise price $ 5.00 $ 4.70 Term 10 years 10 years Risk-Free Interest Rate 1.36 % 1.70 % Dividend Yield 0.00 % 0.00 % Volatility 65.55 % 64.14 %
Schedule of option activity	A summary of the Company's stock option activity for the years ended December 31, 2016 and 2015 is presented below. December 31, 2016 December 31, 2015 Number of Options Weighted- Average Exercise Price Number of Options Weighted- Average Exercise Price Options outstanding, beginning of period 4,753,335 $ 3.60 5,669,000 $ 3.68 Granted or deemed issued 2,596,200 $ 4.97 — — Exercised (15,866 ) $ 3.60 (2,000 ) $ 3.60 Cancelled, forfeited and expired (378,469 ) $ 3.91 (913,665 ) $ 4.05 Options outstanding, end of period 6,955,200 $ 4.10 4,753,335 $ 3.60 Options exercisable at end of year 4,372,667 $ 3.59 4,379,335 $ 3.60 Options available for future grant 2,044,800 4,246,665

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of provision (benefit) for income taxes	The provision for income taxes consists of the following for the years ended December 31: 2016 2015 Current U.S. $ 2,400 $ 2,400 International 1,293 1,164 Deferred U.S. — — International — — $ 3,693 $ 3,564
Schedule of deferred tax assets and liabilities	Deferred tax assets consist of the following as of December 31, 2016 and 2015: 2016 2015 Net operating loss carryforward $ 20,881,231 $ 16,650,797 General business tax credit 7,504,146 6,510,162 Stock options 7,633,468 6,271,690 Charitable contribution 56,617 79,944 Accrued expenses 384,690 290,083 Other 412,630 444,929 Total gross deferred tax assets 36,872,782 30,247,605 Less valuation allowance (36,740,418 ) (30,116,742 ) Net deferred tax assets $ 132,364 $ 130,863 Deferred tax liabilities consist of the following as of December 31, 2016 and 2015: 2016 2015 Unrealized gain on foreign exchange translation and others $ (83,880 ) $ (99,228 ) Unrealized gain on securities available-for-sale (48,484 ) (31,635 ) Total deferred tax liability $ (132,364 ) $ (130,863 )
Schedule of income tax provision computed using the statutory federal tax rate	The income tax provision differs from that computed using the statutory federal tax rate of 34%, due to the following: 2016 2015 Tax benefit at statutory federal rate $ (7,481,009 ) $ (4,295,120 ) State taxes, net of federal tax benefit (695,697 ) (469,692 ) Increase in valuation allowance 6,640,524 4,948,921 Permanent items 3,633,702 675,959 General business tax credit (993,983 ) (789,556 ) Other (1,099,844 ) (66,948 ) $ 3,693 $ 3,564

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments	Future minimum lease payments under the agreements are as follows: Year Amount 2017 553,956 2018 538,498 2019 126,115 Total $ 1,218,569

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Schedule of related parties outstanding loans	The following table sets forth information relating to the Company's loans from related persons outstanding as of December 31, 2016. Class Lender Annual Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2016 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes at December 31, 2016 Notes payable to related parties—current: Hope Hospice(1) 8 % 1/17/2012 Due on demand $ 200,000 $ 200,000 $ — $ 20,000 $ — — Hope Hospice(1) 8 % 6/14/2012 Due on demand 200,000 200,000 — 20,000 — — Hope Hospice(1) 8 % 6/21/2012 Due on demand 100,000 100,000 — 10,000 — — Hope Hospice(1) 8 % 2/11/2013 Due on demand 50,000 50,000 — 5,000 — — Hope Hospice(1) 10 % 1/7/2015 Due on demand 100,000 100,000 — — — — Lan T. Tran(2) 10 % 2/9/2015 Due on demand 10,000 10,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum(2) 10 % 2/20/2015 Due on demand 10,000 10,000 — — — — Yutaka Niihara(2)(3) 10 % 5/21/2015 Due on demand 94,340 826,105 731,765 47,822 — — Masaharu & Emiko Osato(3) 11 % 12/29/2015 Due on demand 300,000 300,000 — — — — Lan T. Tran(2) 11 % 2/10/2016 Due on demand 130,510 130,510 — — — — Hideki & Eiko Uehara(4) 11 % 2/15/2016 Due on demand — 133,333 133,333 12,226 3.50 — Masaharu & Emiko Osato(3) 11 % 2/25/2016 Due on demand 400,000 400,000 — — — — Hope Hospice(1) 10 % 4/4/2016 Due on demand 50,000 50,000 — — — — Willis C. Lee(2)(3) 10 % 4/8/2016 Due on demand — 79,700 79,700 1,288 — — Lan T. Tran(2) 10 % 4/29/2016 Due on demand 20,000 20,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum(2) 10 % 5/5/2016 Due on demand 10,000 10,000 — — — — Hope Hospice(1) 10 % 6/3/2016 Due on demand 250,000 250,000 — — — — Sub total $ 1,924,850 $ 2,869,648 $ 944,798 $ 116,336 $ — — Convertible notes payable to related parties—current: Yasushi Nagasaki(2) 10 % 6/29/2012 Due on demand $ 254,000 $ 388,800 $ 134,800 $ 27,824 $ 3.30 94,532 Charles & Kimxa Stark(2) 10 % 10/1/2015 2 years 20,000 20,000 — — 4.50 5,002 Yutaka & Soomi Niihara(2)(3) 10 % 11/16/2015 2 years 200,000 200,000 — — 4.50 49,461 Sub total $ 474,000 $ 608,800 $ 134,800 $ 27,824 — 148,995 Total $ 2,398,850 $ 3,478,448 $ 1,079,598 $ 144,160 — 148,995 (1) Dr. Niihara, who is the Company's CEO, is also the CEO of Hope Hospice. (2) Officer (3) Director (4) Family of Officer/Director The following table sets forth information relating to the Company's loans from related persons outstanding as of December 31, 2015. Class Lender Annual Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2015 Highest Principal Outstanding Amount of Principal Repaid Amount of Interest Paid Conversion Rate Shares Underlying Notes at December 31, 2015 Notes payable to related parties—current: Hope Hospice(1) 8 % 1/17/2012 Due on demand $ 200,000 $ 200,000 $ — $ 8,000 $ — — Hope Hospice(1) 8 % 6/14/2012 Due on demand 200,000 200,000 — 8,000 — — Hope Hospice(1) 8 % 6/21/2012 Due on demand 100,000 100,000 — 4,000 — — Yutaka Niihara(2)(4) 10 % 12/5/2012 Due on demand 126,729 1,213,700 1,086,970 56,722 — — Hope Hospice(1) 8 % 2/11/2013 Due on demand 50,000 50,000 — 2,000 — — Lan T. Tran(2) 11 % 2/10/2014 Due on demand 106,976 106,976 — — — — Hideki & Eiko Uehara(5) 11 % 2/15/2014 2 years 133,333 133,333 — — — — Hope Hospice(1) 10 % 1/7/2015 Due on demand 100,000 100,000 — — — — James Lee(5) 10 % 1/26/2015 Due on demand 50,000 50,000 — — — — Hope Hospice(1) 10 % 1/29/2015 Due on demand 30,000 30,000 — — — — Yutaka Niihara(2)(4) 10 % 1/29/2015 Due on demand — 20,000 20,000 773 Lan T. Tran(2) 10 % 2/9/2015 Due on demand 10,000 10,000 — — — — Charles Stark(2) 10 % 2/10/2015 Due on demand 10,000 10,000 — — — — IRA Service Trust Co. FBO Peter B. Ludlum(2) 10 % 2/20/2015 Due on demand 10,000 10,000 — — — — Cuc T. Tran(5) 11 % 3/5/2015 1 year 13,161 13,161 — — — — Yutaka Niihara(2)(4) 10 % 4/7/2015 Due on demand 500,000 500,000 — — — — Yutaka Niihara(2)(4) 10 % 5/21/2015 Due on demand 826,105 826,105 — — — — Masaharu & Emiko Osato(4) 11 % 12/29/2015 Due on demand 300,000 300,000 — — — — Sub total $ 2,766,304 $ 3,873,275 $ 1,106,970 $ 79,495 $ — — Convertible notes payable to related parties—current: Yasushi Nagasaki(2) 10 % 6/29/2012 Due on demand $ 298,000 $ 388,800 $ 90,800 $ — $ 3.30 108,505 Sub total $ 298,000 $ 388,800 $ 90,800 $ — $ — 108,505 Non-Current, convertible notes payable to related parties: Yutaka Niihara(2)(4) 10 % 9/29/2015 2 years $ 100,000 $ 100,000 $ — $ — $ 4.50 22,794 Charles & Kimxa Stark(2) 10 % 10/1/2015 2 years 20,000 20,000 — — 4.50 4,556 Yutaka & Soomi Niihara(2)(4) 10 % 11/16/2015 2 years 200,000 200,000 4.50 45,004 Sub total 320,000 320,000 $ — $ — $ — 72,354 Total $ 3,384,304 $ 4,582,075 $ 1,197,770 $ 79,495 $ — 180,859 (1) Dr. Niihara is the Chief Executive Officer of Hope Hospice. (2) Officer. (3) Director. (4) Family of officer or director.

GEOGRAPHIC INFORMATION (Tables)

GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of revenue earned from countries outside of the United States	For the years ended December 31, 2016 and 2015, the Company earned revenue from countries outside of the United States as outlined in the table below. Country Revenue for the year ended December 31, 2016 % of Total Revenue year ended December 31, 2016 Revenue for the year ended December 31, 2015 % of Total Revenue year ended December 31, 2015 Japan $ 160,543 35 % $ 194,142 33 % Taiwan 220,397 48 % 277,637 47 % South Korea — 0 % 39,660 7 %

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Schedule of subsequent events	Subsequent to the year ended December 31, 2016, the Company issued the following: Notes Issued after December 31, 2016 Principal Amounts Annual Interest Rate Term of Notes Conversion Price Convertible notes(1) $ 504,312 10 % Due on Demand to 2 Years $ 3.60 Convertible notes(1) 1,130,536 10 % 6 Months to 2 Years $ 3.50 Convertible note 200,000 10 % Due on Demand to 6 Months $ 7.60 Promissory note(1)(2) 605,315 11 % Due on Demand Promissory notes—related party(1) 12,000 10 % Due on Demand — Total $ 2,452,163 (1) Refinancings of prior notes already outstanding. (2) Principal amount of note is JPY68,320,000 which was converted into US dollars using an exchange rate of 0.008860 as of February 17, 2017.

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounts payable and accrued expenses	$ 3,201,154	$ 4,580,494
Total current liabilities	18,899,440	18,390,225
Total liabilities	30,554,478	30,839,984
Accumulated deficit	(106,760,656)	(85,581,809)
Total stockholder's deficit	$ (17,561,900)	(29,362,986)	$ (21,178,662)
As Previously Reported [Member]
Accounts payable and accrued expenses		3,780,494
Total current liabilities		17,590,225
Total liabilities		30,039,984
Accumulated deficit		(84,781,809)
Total stockholder's deficit		(28,562,986)
Adjustment [Member]
Accounts payable and accrued expenses		800,000
Total current liabilities		800,000
Total liabilities		800,000
Accumulated deficit		(800,000)
Total stockholder's deficit		$ (800,000)

DESCRIPTION OF BUSINESS (Deta31

DESCRIPTION OF BUSINESS (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
General and adminstrative	$ 9,342,635	$ 10,219,683
Loss from operations	(11,528,502)	(12,602,582)
Loss before income taxes	$ (21,175,154)	(13,494,409)
As Previously Reported [Member]
General and adminstrative		9,419,683
Loss from operations		(11,802,582)
Loss before income taxes		(12,694,409)
Adjustment [Member]
General and adminstrative		800,000
Loss from operations		(800,000)
Loss before income taxes		$ (800,000)

DESCRIPTION OF BUSINESS (Deta32

DESCRIPTION OF BUSINESS (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (21,178,847)	$ (13,497,973)
Accounts payable and accrued expenses	$ 43,672	2,407,203
As Previously Reported [Member]
Net loss		(12,697,973)
Accounts payable and accrued expenses		1,607,203
Adjustment [Member]
Net loss		(800,000)
Accounts payable and accrued expenses		$ 800,000

DESCRIPTION OF BUSINESS (Deta33

DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)	Nov. 19, 2015	Mar. 31, 2011	Oct. 31, 2010
Settlement Agreement [Member] | Sarissa Capital Management L.P. [Member]
Settlement amount payable but not recorded in prior year report	$ 800,000
Emmaus Medical Japan, Inc [Member]
Percentage of acquired interest		3.00%	97.00%
Aggregate formation cost			$ 52,500

SUMMARY OF SIGNIFICANT ACCOUN34

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Work-in-process	$ 34,462	$ 45,355
Finished goods	131,747	173,808
Total	$ 166,209	$ 219,163

SUMMARY OF SIGNIFICANT ACCOUN35

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Prepaid insurance	$ 100,060	$ 97,708
Other prepaid expenses and current assets	29,144	33,405
Prepaid expenses and other current assets	$ 129,204	$ 131,113

SUMMARY OF SIGNIFICANT ACCOUN36

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Liability Classified Warrants - Stock Purchase Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period		$ 3,206,000
Reclassification to warrant derivative liabilities		(2,545,000)
Change in fair value included in the statement of comprehensive loss		(661,000)
Warrant Derivative Liabilities - Stock Purchase Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 7,863,000	6,520,000
Reclassification from liability classified warrants		2,545,000
Change in fair value included in the statement of comprehensive loss	2,737,000	(1,202,000)
Balance, end of period	$ 10,600,000	$ 7,863,000

SUMMARY OF SIGNIFICANT ACCOUN37

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($)	Sep. 11, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Balance, end of period:
Warrant derivative liabilities		$ 10,600,000	$ 7,863,000
Warrants [Member]
Stock price	$ 3.60	$ 6	$ 4.70	$ 4.90	$ 3.60
Risk-free interest rate	1.72%	1.09%	1.23%	1.38%	1.75%
Expected volatility (peer group)	72.40%	68.30%	64.10%	71.50%	63.20%
Expected life (in years)	5 years	1 year 8 months 12 days	2 years 8 months 12 days	3 years 8 months 12 days	4 years 8 months 12 days
Number outstanding	3,320,501	3,320,501	3,320,501	3,320,501	3,320,501
Balance, end of period:
Liability classified warrants	$ 7,541,000			$ 3,206,000	$ 6,517,000
Warrant derivative liabilities		$ 10,600,000	$ 7,863,000	$ 6,520,000

SUMMARY OF SIGNIFICANT ACCOUN38

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)	12 Months Ended
	Dec. 31, 2016USD ($)$ / shares$ / Warrantsshares
Original Loan Principal Amount	$ 16,212,313
Beneficial Conversion Discount Amount	$ 4,584,745
Warrants Issued with Notes (in shares) | shares	304,167
Warrant FMV Discount Amount	$ 855,731
Minimum [Member]
Conversion Rate (in dollars per share) | $ / shares	$ 3.05
Maximum [Member]
Conversion Rate (in dollars per share) | $ / shares	$ 3.60
2015 Convertible Notes Payable [Member]
Stated Annual Interest Rate	10.00%
Original Loan Principal Amount	$ 4,051,022
Beneficial Conversion Discount Amount	$ 1,388,201
Warrants Issued with Notes (in shares) | shares	110,417
Excrcise Price (in dollars per share) | $ / Warrants	4.90
Warrant FMV Discount Amount	$ 220,071
2015 Convertible Notes Payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion Rate (in dollars per share) | $ / shares	$ 3.05
Effective Interest Rate Including Discounts	14.00%
2015 Convertible Notes Payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion Rate (in dollars per share) | $ / shares	$ 4.50
Effective Interest Rate Including Discounts	109.00%
2016 Convertible Notes Payable [Member]
Term of Notes	Due on demand ~ 1 year
Stated Annual Interest Rate	10.00%
Original Loan Principal Amount	$ 10,866,291
Beneficial Conversion Discount Amount	$ 3,196,544
Warrants Issued with Notes (in shares) | shares	75,000
Excrcise Price (in dollars per share) | $ / Warrants	4.70
Warrant FMV Discount Amount	$ 161,658
2016 Convertible Notes Payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion Rate (in dollars per share) | $ / shares	$ 3.50
Effective Interest Rate Including Discounts	14.00%
2016 Convertible Notes Payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion Rate (in dollars per share) | $ / shares	$ 4.50
Effective Interest Rate Including Discounts	102.00%
2016 Promissory Notes Payable [Member]
Stated Annual Interest Rate	10.00%
Original Loan Principal Amount	$ 1,295,000
Warrants Issued with Notes (in shares) | shares	118,750
Excrcise Price (in dollars per share) | $ / Warrants	4.50
Warrant FMV Discount Amount	$ 474,002
2016 Promissory Notes Payable [Member] | Minimum [Member]
Term of Notes	11 months 15 days
2016 Promissory Notes Payable [Member] | Maximum [Member]
Term of Notes	12 months 15 days

SUMMARY OF SIGNIFICANT ACCOUN39

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Oct. 31, 2016USD ($)Number$ / shares	Jan. 31, 2009USD ($)Number$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares
Net loss | $			$ (21,178,847)	$ (13,497,973)
Advertising costs | $			$ 35,622	62,388
Impairment of intangible assets | $				$ 678,571
Potentially dilutive securities outstanding | shares			15,462,936	11,453,596
AFH Advisory [Member]
Gain on derecognition of amounts due to related party | $				$ 394,446
2011 Convertible notes payable [Member]
Convertible notes payable, carrying amount | $			$ 300,000
Cell Seed Inc [Member]
Shares held as marketable securities | shares			39,250
Shares originally purchased (in shares) | shares		147,100
Investment, in dollars | $		$ 1,109,819
Investment, closing price			$ 5.74	$ 5.58
Stock pledged against note | shares			39,250
Cell Seed Inc [Member] | Japanese Yen [Member]
Investment, in yen | Number		100,028,000
Investment, in per share		$ 680
Investment, closing price			$ 536	$ 672
KPM Tech [Member]
Shares held as marketable securities | shares			849,744
Investment, in dollars | $	$ 13,000,000
Investment, closing price			$ 12.08
KPM Tech [Member] | South Korean Won [Member]
Investment, in won | Number	14,318,186,400
Investment, in per share	$ 16,850
Investment, closing price			$ 14,600
Hanil Vacuum [Member]
Shares held as marketable securities | shares			271,950
Investment, in dollars | $	$ 1,000,000
Investment, closing price			$ 2.40
Hanil Vacuum [Member] | South Korean Won [Member]
Investment, in won | Number	1,101,397,500
Investment, in per share	$ 4,050
Investment, closing price			$ 2,895
Minimum [Member]
Intangible assets, useful life			3 years
Maximum [Member]
Intangible assets, useful life			7 years
Furniture and Fixtures [Member] | Minimum [Member]
Useful life			5 years
Furniture and Fixtures [Member] | Maximum [Member]
Useful life			7 years

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property and equipment
Property and equipment, gross	$ 280,974	$ 270,192
Less: accumulated depreciation	(227,244)	(211,965)
Property and equipment, net	53,730	58,227
Equipment [Member]
Property and equipment
Property and equipment, gross	175,410	164,931
Leasehold Improvements [Member]
Property and equipment
Property and equipment, gross	30,804	30,579
Furniture and Fixtures [Member]
Property and equipment
Property and equipment, gross	$ 74,760	$ 74,682

PROPERTY AND EQUIPMENT (Detai41

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 15,279	$ 18,893

ACCOUNTS PAYABLE AND ACCRUED 42

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounts payable
Clinical and regulatory expenses	$ 145,239	$ 322,193
Legal expenses	43,700	242,384
Consulting fees	99,800	74,700
Accounting fees	65,267	230,598
Selling expenses	60,724	34,279
Investor relations and public relations expenses	19,931	18,097
Other vendors	41,640	318,269
Total accounts payable	476,301	1,240,520
Accrued interest payable, related parties	274,851	176,940
Accrued interest payable	1,441,450	1,586,472
Accrued expenses	716,886	1,284,896
Deferred salary	291,666	291,666
Total accounts payable and accrued expenses	$ 3,201,154	$ 4,580,494

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Principal Outstanding	$ 18,276,376	$ 19,128,039
Discount Amount	1,580,133	879,766
Carrying Amount	16,696,243	18,248,273
Notes payable, current	$ 4,094,429	4,656,749
Minimum [Member]
Conversion price	$ 3.05
Maximum [Member]
Conversion price	$ 3.60
2013 Notes payable [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 854,900	830,000
Carrying Amount	$ 854,900	$ 830,000
2014 Notes payable [Member]
Interest rate	11.00%
Term of Notes		Due on demand ~ 2 years
Principal Outstanding		$ 1,446,950
Carrying Amount		1,446,950
2015 Notes payable [Member]
Interest rate	11.00%
Term of Notes	Due on demand
Principal Outstanding	$ 2,406,194	2,379,799
Carrying Amount	$ 2,406,194	2,379,799
2016 Notes payable [Member]
Interest rate	11.00%
Term of Notes	Due on demand
Principal Outstanding	$ 833,335
Carrying Amount	833,335
Notes Payable [Member]
Principal Outstanding	4,094,429	4,656,749
Carrying Amount	4,094,429	4,656,749
Principal Outstanding, current	4,094,429	4,656,749
Notes payable, current	$ 4,094,429	4,656,749
2012 Notes payable - related party [Member]
Interest rate	8.00%
Term of Notes	Due on demand
Principal Outstanding	$ 500,000	626,730
Carrying Amount	$ 500,000	626,730
2013 Notes payable - related party [Member]
Interest rate	8.00%
Term of Notes	Due on demand
Principal Outstanding	$ 50,000	50,000
Carrying Amount	$ 50,000	$ 50,000
2014 Notes payable - related party [Member]
Interest rate	11.00%
Term of Notes		Due on demand ~ 2 years
Principal Outstanding		$ 240,308
Carrying Amount		240,308
2015 Notes payable - related party [Member]
Term of Notes	Due on demand
Principal Outstanding	$ 514,340	1,849,266
Carrying Amount	$ 514,340	1,849,266
2015 Notes payable - related party [Member] | Minimum [Member]
Interest rate	10.00%
2015 Notes payable - related party [Member] | Maximum [Member]
Interest rate	11.00%
2016 Notes payable - related party [Member]
Term of Notes	Due on demand
Principal Outstanding	$ 860,510
Carrying Amount	$ 860,510
2016 Notes payable - related party [Member] | Minimum [Member]
Interest rate	10.00%
2016 Notes payable - related party [Member] | Maximum [Member]
Interest rate	11.00%
Notes payable - related party [Member]
Principal Outstanding	$ 1,924,850	2,766,304
Carrying Amount	1,924,850	2,766,304
Principal Outstanding, current	1,924,850	2,766,304
Notes payable, current	$ 1,924,850	$ 2,766,304

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1)	12 Months Ended
	Dec. 31, 2016USD ($)Number$ / shares	Dec. 31, 2015USD ($)Number	Aug. 26, 2016$ / shares
Principal Outstanding	$ 18,276,376	$ 19,128,039
Discount Amount	1,580,133	879,766
Total Carrying Amount	$ 16,696,243	$ 18,248,273
Shares Underlying Principal | Number	3,483,068	3,169,343
Convertible notes payable, Current	$ 9,205,007	$ 6,000,347
Convertible notes payable, Non Current	$ 997,957	4,206,873
Minimum [Member]
Conversion price | $ / shares	$ 3.05
Maximum [Member]
Conversion price | $ / shares	$ 3.60
2010 Convertible notes payable [Member]
Interest rate	6.00%
Term of Notes	5 years
Conversion price | $ / shares	$ 3.05
Principal Outstanding		2,000
Total Carrying Amount		$ 2,000
Shares Underlying Principal | Number		656
2011 Convertible notes payable [Member]
Interest rate	10.00%
Term of Notes	5 years
Conversion price | $ / shares	$ 3.05
Principal Outstanding	$ 300,000	$ 500,000
Total Carrying Amount	$ 300,000	$ 500,000
Shares Underlying Principal | Number	98,285	163,809
2013 Convertible notes payable [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion price | $ / shares	$ 3.60
Principal Outstanding		$ 525,257
Total Carrying Amount		$ 525,257
Shares Underlying Principal | Number		185,553
2014 Convertible notes payable [Member]
Interest rate	10.00%
Term of Notes	Due on demand ~ 2 years
Principal Outstanding	$ 452,168	$ 4,378,563
Discount Amount		353,700
Total Carrying Amount	$ 452,168	$ 4,024,863
Shares Underlying Principal | Number	152,986	1,120,470
2014 Convertible notes payable [Member] | Minimum [Member]
Conversion price | $ / shares	$ 3.05
2014 Convertible notes payable [Member] | Maximum [Member]
Conversion price | $ / shares	$ 3.60
2015 Convertible notes payable [Member]
Interest rate	10.00%
Term of Notes	2 years
Principal Outstanding	$ 2,904,800	$ 5,681,166
Discount Amount	104,389	526,066
Total Carrying Amount	$ 2,800,411	$ 5,155,100
Shares Underlying Principal | Number	889,115	1,517,996
2015 Convertible notes payable [Member] | Minimum [Member]
Conversion price | $ / shares	$ 3.50
2015 Convertible notes payable [Member] | Maximum [Member]
Conversion price | $ / shares	$ 3.60
2016 Convertible Notes Payable [Member]
Interest rate	10.00%
Term of Notes	Due on demand ~ 1 year
Principal Outstanding	$ 8,126,129
Discount Amount	1,475,744
Total Carrying Amount	$ 6,650,385
Shares Underlying Principal | Number	2,193,687
2016 Convertible Notes Payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion price | $ / shares	$ 3.50
2016 Convertible Notes Payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion price | $ / shares	$ 4.50
Convertible Notes Payable [Member]
Conversion price | $ / shares			$ 3.50
Principal Outstanding	$ 11,783,097	$ 11,086,986
Discount Amount	1,580,133	879,766
Total Carrying Amount	$ 10,202,964	$ 10,207,220
Shares Underlying Principal | Number	3,334,073	2,988,484
Principal Outstanding, Current	$ 10,499,303	$ 6,358,698
Principal Outstanding, Non Current	1,283,794	4,728,288
Discount Amount Current	1,294,296	358,351
Discount Amount Non Current	285,837	521,415
Convertible notes payable, Current	9,205,007	6,000,347
Convertible notes payable, Non Current	$ 997,957	$ 4,206,873
Shares Underlying Principal Current | Number	2,984,161	1,762,849
Shares Underlying Principal Non Current | Number	349,912	1,225,635
2012 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Conversion price | $ / shares	$ 3.30
Principal Outstanding	$ 254,000	$ 298,000
Total Carrying Amount	$ 254,000	$ 298,000
Shares Underlying Principal | Number	94,532	108,505
2015 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion price | $ / shares	$ 4.50
Principal Outstanding	$ 220,000	$ 320,000
Total Carrying Amount	$ 220,000	$ 320,000
Shares Underlying Principal | Number	54,463	72,354
Convertible notes payable - related party [Member]
Principal Outstanding	$ 474,000	$ 618,000
Total Carrying Amount	$ 474,000	$ 618,000
Shares Underlying Principal | Number	148,995	108,859
Principal Outstanding, Current	$ 474,000	$ 298,000
Principal Outstanding, Non Current		320,000
Convertible notes payable related parties, Current	$ 474,000	298,000
Convertible notes payable related parties, Non Current		$ 320,000
Shares Underlying Principal Current | Number	148,995	108,505
Shares Underlying Principal Non Current | Number		72,354

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2)	Dec. 31, 2015USD ($)
Contractual principal payments due on loans and notes payable for the year ending
2,017	$ 16,992,582
2,018	1,283,794
Total	$ 18,276,376

NOTES PAYABLE (Details 3)

NOTES PAYABLE (Details 3) - $ / shares	Sep. 11, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	May 10, 2016	Jan. 14, 2016	Sep. 09, 2013	Dec. 31, 2012
Stock price						$ 5	$ 4.70
Warrants [Member]
Stock price			$ 6	$ 4.70	$ 4.90			$ 3.60	$ 3.60
Term	5 years	1 year 8 months 12 days	2 years 8 months 12 days	3 years 8 months 12 days	4 years 8 months 12 days
Risk-free interest rate	1.72%	1.09%	1.23%	1.38%	1.75%
Expected volatility	72.40%	68.30%	64.10%	71.50%	63.20%
Warrants [Member] | Convertible Notes Payable [Member]
Stock price		$ 5	$ 4.50
Exercise Price			$ 4.90
Term		5 years	5 years
Risk-free interest rate			1.57%
Expected volatility			67.30%
Warrants [Member] | Convertible Notes Payable [Member] | Minimum [Member]
Exercise Price		$ 4.50
Risk-free interest rate		1.01%
Expected volatility		65.40%
Warrants [Member] | Convertible Notes Payable [Member] | Maximum [Member]
Exercise Price		$ 4.70
Risk-free interest rate		1.28%
Expected volatility		69.60%

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Average stated interest rate	10.00%	10.00%
Average effective interest rate	27.00%	23.00%
Description of debt conversion	Certain notes with a $4.50 and a $7.00 stated conversion price in the second year of their two-year term are subject to automatic conversion into shares of the Company's common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering.
Warrants [Member]
Method of calculation of fair value of warrants	Black-Scholes-Merton option pricing model
Minimum [Member]
Conversion price	$ 3.05
Maximum [Member]
Conversion price	$ 3.60

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Warrants outstanding summary
Warrants outstanding, ending	5,024,668
Warrants [Member]
Warrants outstanding summary
Warrants outstanding, beginning	3,530,918	5,101,450
Granted	1,493,750	110,417
Exercised		(148,256)
Cancelled, forfeited and expired		(1,532,693)
Warrants outstanding, ending	5,024,668	3,530,918

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details 1)	12 Months Ended
	Dec. 31, 2016Numbershares
Outstanding
Warrants outstanding	5,024,668
Exercisable	5,024,668
Warrants Issued in 2013 - Exercise Price $3.30 [Member]
Outstanding
Warrants outstanding	50,000
Weighted Average Remaining Contractual Life (Years)	1 year 3 months 29 days
Weighted Average Exercise Price | Number	3.30
Exercisable	50,000
Weighted Average Exercise Price | Number	3.30
Warrants Issued in 2013 - Exercise Price $3.50 [Member]
Outstanding
Warrants outstanding	2,225,036
Weighted Average Remaining Contractual Life (Years)	1 year 8 months 12 days
Weighted Average Exercise Price | Number	3.50
Exercisable	2,225,036
Weighted Average Exercise Price | Number	3.50
Warrants Issued in 2013 [Member]
Outstanding
Warrants outstanding	2,275,036
Exercisable	2,275,036
Warrants Issued in 2014 - Exercise Price $3.50 [Member]
Outstanding
Warrants outstanding	1,145,465
Weighted Average Remaining Contractual Life (Years)	1 year 8 months 19 days
Weighted Average Exercise Price | Number	3.50
Exercisable	1,145,465
Weighted Average Exercise Price | Number	3.50
Warrants Issued in 2014 [Member]
Outstanding
Warrants outstanding	1,145,465
Exercisable	1,145,465
Warrants Issued in 2015 - Exercise Price $4.90 [Member]
Outstanding
Warrants outstanding	110,417
Weighted Average Remaining Contractual Life (Years)	3 years 2 months 5 days
Weighted Average Exercise Price | Number	4.90
Exercisable	110,417
Weighted Average Exercise Price | Number	4.90
Warrants Issued in 2015 [Member]
Outstanding
Warrants outstanding	110,417
Exercisable	110,417
Warrants Issued in 2016 - Exercise Price $4.50 [Member]
Outstanding
Warrants outstanding	118,750
Weighted Average Remaining Contractual Life (Years)	4 years 6 months
Weighted Average Exercise Price | Number	4.50
Exercisable	118,750
Weighted Average Exercise Price | Number	4.50
Warrants Issued in 2016 - Exercise Price $4.70 [Member]
Outstanding
Warrants outstanding	75,000
Weighted Average Remaining Contractual Life (Years)	4 years 3 months 29 days
Weighted Average Exercise Price | Number	4.70
Exercisable	75,000
Weighted Average Exercise Price | Number	4.70
Warrants Issued in 2016 - Exercise Price $5.00 [Member]
Outstanding
Warrants outstanding	1,300,000
Weighted Average Remaining Contractual Life (Years)	4 years 4 months 10 days
Weighted Average Exercise Price | Number	5
Exercisable	1,300,000
Weighted Average Exercise Price | Number	5

STOCKHOLDERS' DEFICIT (Detail50

STOCKHOLDERS' DEFICIT (Details 2) - $ / shares	May 10, 2016	Jan. 14, 2016
Stockholders' Equity Note [Abstract]
Stock price	$ 5	$ 4.70
Exercise price	$ 5	$ 4.70
Term	10 years	10 years
Risk-Free Interest Rate	1.36%	1.70%
Dividend Yield	0.00%	0.00%
Volatility	65.55%	64.14%

STOCKHOLDERS' DEFICIT (Detail51

STOCKHOLDERS' DEFICIT (Details 3) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options, Outstanding [Roll Forward]
Granted or deemed issued	2,596,200
2011 Stock Incentive Option Plan [Member]
Options, Outstanding [Roll Forward]
Options outstanding, beginning	4,753,335	5,669,000
Granted or deemed issued	2,596,200
Exercised	(15,866)	(2,000)
Cancelled, forfeited and expired	(378,469)	(913,665)
Options outstanding, end	6,955,200	4,753,335
Options exercisable	4,372,667	4,379,335
Options available for future grant	2,044,800	4,246,665
Weighted Average Exercise Price [Roll Forward]
Options outstanding, beginning	$ 3.60	$ 3.68
Granted or deemed issued	4.97
Exercised	3.60	3.60
Cancelled, forfeited and expired	3.91	4.05
Options outstanding, end	4.10	3.60
Options exercisable	$ 3.59	$ 3.60

STOCKHOLDERS' DEFICIT (Detail52

STOCKHOLDERS' DEFICIT (Details Narrative)	Sep. 12, 2016USD ($)$ / sharesshares	Aug. 26, 2016USD ($)Number$ / shares	Jun. 10, 2014USD ($)$ / sharesshares	Sep. 11, 2013USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	May 10, 2016$ / shares	Jan. 14, 2016$ / shares	Jun. 10, 2015USD ($)shares	Dec. 31, 2014$ / sharesshares	Sep. 11, 2014USD ($)shares	Jul. 14, 2014shares	Dec. 31, 2013$ / shares	Sep. 09, 2013$ / shares	Feb. 28, 2013shares	Feb. 27, 2013shares	Dec. 31, 2012$ / shares
Warrants outstanding | shares					5,024,668
Fair value of outstanding warrants					$ 10,600,000	$ 7,863,000
Proceeds from exercise of warrants					$ 4,890,105	18,000
Issuance of warrants (in shares) | shares					304,167
Options granted | shares					2,596,200
Share-based compensation					$ 3,328,400	3,708,801
Share price | $ / shares							$ 5	$ 4.70
Convertible note inducement expense					1,444,863
Loss on debt settlement					$ (266,736)
Conversion of nonconvertible notes payable to common stock						$ 102,885
Convertible Notes Payable [Member]
Converted debt amount		$ 4,007,598
Conversion price | $ / shares		$ 3.50
Accrued interest		$ 260,124
Number of note holders | Number		19
Convertible note inducement expense		$ 1,444,863
Notes Payable [Member]
Converted debt amount		622,384
Loss on debt settlement		(266,736)
Conversion of nonconvertible notes payable to common stock		$ 889,120
KPM Tech Co., Ltd [Member] | Letter of Agreement [Member]
Common stock price | $ / shares					$ 15.32
Future capital increases					$ 13,000,000
Hanil Vacuum Co Ltd [Member] | Letter of Agreement [Member]
Common stock price | $ / shares					$ 3.68
Future capital increases					$ 1,000,000
Maximum [Member]
Conversion price | $ / shares					$ 3.60
Minimum [Member]
Conversion price | $ / shares					$ 3.05
2011 Stock Incentive Option Plan [Member]
Options granted | shares					2,596,200
Exercise price - options | $ / shares					$ 4.10	$ 3.60				$ 3.68
Options outstanding | shares					6,955,200	4,753,335				5,669,000
Total unrecognized compensation cost					$ 8,000,000
Period remaining for recognition of unrecognized compensation cost					2 years 1 month 6 days
2011 Stock Incentive Option Plan [Member] | Stock Options [Member]
Number of shares authorized under the plan | shares					9,000,000							9,000,000			6,000,000	3,000,000
Expiration period					10 years
Vesting period					3 years
Share-based compensation					$ 3,300,000	$ 3,700,000
2011 Stock Incentive Option Plan [Member] | 2016 Stock Options Tranche 1 [Member]
Options granted | shares					300,000
Exercise price - options | $ / shares					$ 4.70
Vesting percentage					33.00%
2011 Stock Incentive Option Plan [Member] | 2016 Stock Options Tranche 2 [Member]
Options granted | shares					2,296,200
Exercise price - options | $ / shares					$ 5
Vesting percentage					33.00%
Warrants [Member]
Share price | $ / shares						$ 6				$ 4.70			$ 4.90	$ 3.60			$ 3.60
Warrants [Member] | Convertible Notes Payable [Member]
Share price | $ / shares					$ 5	$ 4.50
Cashless Exercise Warrants [Member]
Warrants outstanding | shares					3,320,501
Number of shares callable by warrants | shares					1,660,251
Increase fair value of common stock | $ / shares					$ 1
Cashless Exercise Warrants [Member] | Maximum [Member]
Number of shares callable by warrants | shares					1,383,542
Share price | $ / shares					$ 6
Cashless Exercise Warrants [Member] | Minimum [Member]
Share price | $ / shares					$ 7
Private Placement [Member]
Units issued in offering (in units) | shares				3,020,501
Unit price of offering | shares				2.50
Units issued in offering				$ 7,551,253
Warrants issued to broker of the offering | shares				300,000
Exercise price | $ / shares			$ 3.50	$ 3.50
Warrants outstanding | shares											2,225,036
Fair value of outstanding warrants			$ 1,800,000								$ 7,068,000
Number of warrants exercised | shares			1,095,465
Proceeds from exercise of warrants			$ 3,800,000
Issuance of common stock for exercise of warrants | shares			1,095,465
Adjustment ot additional paid-in capital - warrants			$ 1,800,000
Number of registrable securities (shares) | shares											4,115,966
Private Placement [Member] | Letter of Agreement [Member]
Common stock price | $ / shares	$ 4.50
Reduction in additional paid in capital	$ 720,000
Private Placement [Member] | KPM Tech Co., Ltd [Member] | Letter of Agreement [Member]
Purchase of common stock	$ 17,000,000
Common stock price | $ / shares	$ 4.50
Future capital investment	$ 13,000,000
Number of shares issued | shares	3,777,778
Private Placement [Member] | Hanil Vacuum Co Ltd [Member] | Letter of Agreement [Member]
Purchase of common stock	$ 3,000,000
Common stock price | $ / shares	$ 4.50
Future capital investment	$ 1,000,000
Number of shares issued | shares	666,667
Private Placement [Member] | Maximum [Member] | Letter of Agreement [Member]
Conversion price | $ / shares		$ 7
Private Placement [Member] | Minimum [Member] | Letter of Agreement [Member]
Conversion price | $ / shares		$ 4.50
Private Placement [Member] | Replacement Warrants [Member]
Exercise price | $ / shares			$ 3.50
Warrants outstanding | shares									1,095,465
Fair value of outstanding warrants									$ 2,545,000
Issuance of warrants (in shares) | shares			1,095,465
Warrant exercise inducement expense			$ 3,500,000
Private Placement [Member] | Warrants [Member]
Number of registrable securities (shares) | shares											3,320,501

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Current
U.S.	$ 2,400	$ 2,400
International	1,293	1,164
Deferred
INCOME TAXES (BENEFIT)	$ 3,693	$ 3,564

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Components of net deferred tax assets
Net operating loss carryforward	$ 20,881,231	$ 16,650,797
General business tax credit	7,504,146	6,510,162
Stock options	7,633,468	6,271,690
Charitable contribution	56,617	79,944
Accrued expenses	384,690	290,083
Other	412,630	444,929
Total gross deferred tax assets	36,872,782	30,247,605
Less valuation allowance	(36,740,418)	(30,116,742)
Net deferred tax assets	$ 132,364	$ 130,863

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Unrealized gain on foreign exchange translation and others	$ (83,880)	$ (99,228)
Unrealized gain on securities available-for-sale	(48,484)	(31,635)
Total deferred tax liability	$ (132,364)	$ (130,863)

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of effective income tax
Tax benefit at statutory federal rate	$ (7,481,009)	$ (4,295,120)
State taxes, net of federal tax benefit	(695,697)	(469,692)
Increase in valuation allowance	6,640,524	4,948,921
Permanent items	3,633,702	675,959
General business tax credit	(993,983)	(789,556)
Other	(1,099,844)	(66,948)
INCOME TAXES (BENEFIT)	$ 3,693	$ 3,564

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Change in valuation allowance	$ 6,623,676	$ 4,923,738
Statutory federal tax rate (in percent)	34.00%
General business tax credits	$ 7,504,000	6,510,000
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration	Dec. 31, 2036
Business credits expiration	Dec. 31, 2026
Net operating loss carryforwards	$ 51,240,000	42,909,000
State and Local
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration	Dec. 31, 2036
Net operating loss carryforwards	$ 49,561,000	$ 40,440,000

COMMITMENTS AND CONTINGENCIES58

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2016USD ($)
Future minimum lease payments
2,017	$ 553,956
2,018	538,498
2,019	126,115
Total	$ 1,218,569

COMMITMENTS AND CONTINGENCIES59

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Monthly commercialization management fee	$ 4,500
Rent expense	$ 589,769	$ 492,919

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)		12 Months Ended
		Dec. 31, 2016USD ($)Number$ / shares		Dec. 31, 2015USD ($)$ / shares	Dec. 31, 2015USD ($)Number$ / shares
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 16,696,243		$ 18,248,273	$ 18,248,273
Shares Underlying Principal | Number		3,483,068			3,169,343
Less discount		$ (1,580,133)		(879,766)	$ (879,766)
Total				$ 18,276,376	$ 18,276,376
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[1]	8.00%		8.00%	8.00%
Date of Loan	[1]	Jan. 17, 2012			Jan. 17, 2012
Term of Loan	[1]	Due on demand			Due on demand
Principal Amount Outstanding	[1]	$ 200,000		$ 200,000	$ 200,000
Highest Principal Outstanding	[1]	200,000		$ 200,000	200,000
Amount of Interest Paid	[1]	$ 20,000			$ 8,000
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[1]	8.00%		8.00%	8.00%
Date of Loan	[1]	Jun. 14, 2012			Jun. 14, 2012
Term of Loan	[1]	Due on demand			Due on demand
Principal Amount Outstanding	[1]	$ 200,000		$ 200,000	$ 200,000
Highest Principal Outstanding	[1]	200,000		$ 200,000	200,000
Amount of Interest Paid	[1]	$ 20,000			$ 8,000
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate		8.00%	[1]	8.00%	8.00%
Date of Loan	[1]	Jun. 21, 2012			Jun. 21, 2012
Term of Loan	[1]	Due on demand			Due on demand
Principal Amount Outstanding	[1]	$ 100,000		$ 100,000	$ 100,000
Highest Principal Outstanding	[1]	100,000		$ 100,000	100,000
Amount of Interest Paid	[1]	$ 10,000			$ 4,000
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2],[3]			10.00%	10.00%
Date of Loan	[2],[3]				Dec. 5, 2012
Term of Loan	[2],[3]				Due on demand
Principal Amount Outstanding	[2],[3]			$ 126,729	$ 126,729
Highest Principal Outstanding	[2],[3]			$ 1,213,700	1,213,700
Amount of Principal Repaid	[2],[3]				1,086,970
Amount of Interest Paid	[2],[3]				$ 56,722
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[1]	8.00%		8.00%	8.00%
Date of Loan	[1]	Feb. 11, 2013			Feb. 11, 2013
Term of Loan	[1]	Due on demand			Due on demand
Principal Amount Outstanding	[1]	$ 50,000		$ 50,000	$ 50,000
Highest Principal Outstanding	[1]	50,000		$ 50,000	50,000
Amount of Interest Paid	[1]	$ 5,000			$ 2,000
Lan T. Tran [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]			11.00%	11.00%
Date of Loan	[3]				Feb. 10, 2014
Term of Loan	[3]				Due on demand
Principal Amount Outstanding	[3]			$ 106,976	$ 106,976
Highest Principal Outstanding	[3]			$ 106,976	$ 106,976
Hideki & Eiko Uehara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[4]			11.00%	11.00%
Date of Loan	[4]			Feb. 15, 2014
Term of Loans	[4]			2 years
Principal Amount Outstanding	[4]			$ 133,333	$ 133,333
Highest Principal Outstanding	[4]			$ 133,333	$ 133,333
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[1]	10.00%		10.00%	10.00%
Date of Loan	[1]	Jan. 7, 2015			Jan. 7, 2015
Term of Loan	[1]	Due on demand			Due on demand
Principal Amount Outstanding	[1]	$ 100,000		$ 100,000	$ 100,000
Highest Principal Outstanding	[1]	$ 100,000		$ 100,000	$ 100,000
James Lee [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[4]			10.00%	10.00%
Date of Loan	[4]				Jan. 26, 2015
Term of Loan	[4]				Due on demand
Principal Amount Outstanding	[4]			$ 50,000	$ 50,000
Highest Principal Outstanding	[4]			$ 50,000	$ 50,000
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[1]			10.00%	10.00%
Date of Loan	[1]				Jan. 29, 2015
Term of Loan	[1]				Due on demand
Principal Amount Outstanding	[1]			$ 30,000	$ 30,000
Highest Principal Outstanding	[1]			$ 30,000	$ 30,000
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2],[3]			10.00%	10.00%
Date of Loan	[2],[3]				Jan. 29, 2015
Term of Loan	[2],[3]				Due on demand
Principal Amount Outstanding	[2],[3]
Highest Principal Outstanding	[2],[3]			$ 20,000	20,000
Amount of Principal Repaid	[2],[3]				20,000
Amount of Interest Paid	[2],[3]				$ 773
Lan T. Tran [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]	10.00%		10.00%	10.00%
Date of Loan	[3]	Feb. 9, 2015			Feb. 9, 2015
Term of Loan	[3]	Due on demand			Due on demand
Principal Amount Outstanding	[3]	$ 10,000		$ 10,000	$ 10,000
Highest Principal Outstanding	[3]	$ 10,000		$ 10,000	$ 10,000
Charles Stark [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]			10.00%	10.00%
Date of Loan	[3]				Feb. 10, 2015
Term of Loan	[3]				Due on demand
Principal Amount Outstanding	[3]			$ 10,000	$ 10,000
Highest Principal Outstanding	[3]			$ 10,000	$ 10,000
IRA Service Trust Co. FBO Peter B. Ludlum [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]	10.00%		10.00%	10.00%
Date of Loan	[3]	Feb. 20, 2015			Feb. 20, 2015
Term of Loan	[3]	Due on demand			Due on demand
Principal Amount Outstanding	[3]	$ 10,000		$ 10,000	$ 10,000
Highest Principal Outstanding	[3]	$ 10,000		$ 10,000	$ 10,000
Cuc T. Tran [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[4]			11.00%	11.00%
Date of Loan	[4]				Mar. 5, 2015
Term of Loans	[4]				1 year
Principal Amount Outstanding	[4]			$ 13,161	$ 13,161
Highest Principal Outstanding	[4]			$ 13,161	$ 13,161
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2],[3]			10.00%	10.00%
Date of Loan	[2],[3]				Apr. 7, 2015
Term of Loan	[2],[3]				Due on demand
Principal Amount Outstanding	[2],[3]			$ 500,000	$ 500,000
Highest Principal Outstanding	[2],[3]			$ 500,000	$ 500,000
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2],[3]	10.00%		10.00%	10.00%
Date of Loan	[2],[3]	May 21, 2015			May 21, 2015
Term of Loan	[2],[3]	Due on demand			Due on demand
Principal Amount Outstanding	[2],[3]	$ 94,340		$ 826,105	$ 826,105
Highest Principal Outstanding	[2],[3]	826,105		$ 826,105	$ 826,105
Amount of Principal Repaid	[2],[3]	731,765
Amount of Interest Paid	[2],[3]	$ 47,822
Masaharu & Emiko Osato [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2]	11.00%		11.00%	11.00%
Date of Loan	[2]	Dec. 29, 2015			Dec. 29, 2015
Term of Loan		Due on demand	[2]		Due on demand
Principal Amount Outstanding	[2]	$ 300,000		$ 300,000	$ 300,000
Highest Principal Outstanding	[2]	300,000		300,000	300,000
Notes payable - related party [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		1,924,850		2,766,304	2,766,304
Highest Principal Outstanding		2,869,648		$ 3,873,275	3,873,275
Amount of Principal Repaid		944,798			1,106,970
Amount of Interest Paid		$ 116,336			$ 79,495
Yasushi Nagasaki [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]	10.00%		10.00%	10.00%
Date of Loan	[3]	Jun. 29, 2012			Jun. 29, 2012
Term of Loan	[3]	Due on demand			Due on demand
Principal Amount Outstanding	[3]	$ 254,000		$ 298,000	$ 298,000
Highest Principal Outstanding	[3]	388,800		$ 388,800	388,800
Amount of Principal Repaid	[3]	134,800			$ 90,800
Amount of Interest Paid	[3]	$ 27,824
Conversion price | $ / shares	[3]	$ 3.3		$ 3.3	$ 3.3
Shares Underlying Principal | Number	[3]	94,532			108,505
Long-term convertible notes payable - related party [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding				$ 320,000	$ 320,000
Highest Principal Outstanding				$ 320,000	$ 320,000
Shares Underlying Principal | Number					72,354
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2],[3]			10.00%	10.00%
Date of Loan	[2],[3]				Sep. 29, 2015
Term of Loans	[2],[3]				2 years
Principal Amount Outstanding	[2],[3]			$ 100,000	$ 100,000
Highest Principal Outstanding	[2],[3]			$ 100,000	$ 100,000
Conversion price | $ / shares	[2],[3]			$ 4.50	$ 4.50
Shares Underlying Principal | Number	[2],[3]				22,794
Notes payable and convertible notes payable - related party [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 2,398,850		$ 3,384,304	$ 3,384,304
Highest Principal Outstanding		3,478,448		4,582,075	4,582,075
Amount of Principal Repaid		1,079,598			1,197,770
Amount of Interest Paid		$ 144,160			$ 79,495
Shares Underlying Principal | Number		148,995			180,859
Convertible notes payable - related party [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 474,000		618,000	$ 618,000
Highest Principal Outstanding		608,800		$ 388,800	388,800
Amount of Principal Repaid		134,800			$ 90,800
Amount of Interest Paid		$ 27,824
Shares Underlying Principal | Number		148,995			108,859
Charles & Kimxa Stark [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]	10.00%		10.00%	10.00%
Date of Loan	[3]	Oct. 1, 2015			Oct. 1, 2015
Term of Loans	[3]	2 years			2 years
Principal Amount Outstanding	[3]	$ 20,000		$ 20,000	$ 20,000
Highest Principal Outstanding	[3]	$ 20,000		$ 20,000	$ 20,000
Conversion price | $ / shares	[3]	$ 4.50		$ 4.50	$ 4.50
Shares Underlying Principal | Number	[3]	5,002			4,556
Yutaka & Soomi Niihara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2],[3]	10.00%		10.00%	10.00%
Date of Loan	[2],[3]	Nov. 16, 2015			Nov. 16, 2015
Term of Loans	[2],[3]	2 years			2 years
Principal Amount Outstanding	[2],[3]	$ 200,000		$ 200,000	$ 200,000
Highest Principal Outstanding	[2],[3]	$ 200,000		$ 200,000	$ 200,000
Conversion price | $ / shares	[2],[3]	$ 4.50		$ 4.50	$ 4.50
Shares Underlying Principal | Number	[2],[3]	49,461			45,004
Lan T. Tran [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]	11.00%
Date of Loan	[3]	Feb. 10, 2016
Term of Loan	[3]	Due on demand
Principal Amount Outstanding	[3]	$ 130,510
Highest Principal Outstanding	[3]	$ 130,510
Hideki & Eiko Uehara [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[4]	11.00%
Date of Loan	[4]	Feb. 15, 2016
Term of Loan	[4]	Due on demand
Highest Principal Outstanding	[4]	$ 133,333
Amount of Principal Repaid	[4]	133,333
Amount of Interest Paid	[4]	$ 12,226
Conversion price | $ / shares	[4]	$ 3.5
Masaharu & Emiko Osato [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2]	11.00%
Date of Loan	[2]	Feb. 25, 2016
Term of Loan	[2]	Due on demand
Principal Amount Outstanding	[2]	$ 400,000
Highest Principal Outstanding	[2]	$ 400,000
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[1]	10.00%
Date of Loan	[1]	Apr. 4, 2016
Term of Loan	[1]	Due on demand
Principal Amount Outstanding	[1]	$ 50,000
Highest Principal Outstanding	[1]	$ 50,000
Willis C. Lee [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[2],[3]	10.00%
Date of Loan	[2],[3]	Apr. 8, 2016
Term of Loan	[2],[3]	Due on demand
Highest Principal Outstanding	[2],[3]	$ 79,700
Amount of Principal Repaid	[2],[3]	79,700
Amount of Interest Paid	[2],[3]	$ 1,288
Lan T. Tran [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]	10.00%
Date of Loan	[3]	Apr. 29, 2016
Term of Loan	[3]	Due on demand
Principal Amount Outstanding	[3]	$ 20,000
Highest Principal Outstanding	[3]	$ 20,000
IRA Service Trust Co. FBO Peter B. Ludlum [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[3]	10.00%
Date of Loan	[3]	May 5, 2016
Term of Loan	[3]	Due on demand
Principal Amount Outstanding	[3]	$ 10,000
Highest Principal Outstanding	[3]	$ 10,000
Hope Hospice [Member]
Short-term Debt [Line Items]
Annual Interest Rate	[1]	10.00%
Date of Loan	[1]	Jun. 3, 2016
Term of Loan	[1]	Due on demand
Principal Amount Outstanding	[1]	$ 250,000
Highest Principal Outstanding	[1]	$ 250,000
[1]	Dr. Niihara, who is the Company's CEO, is also the CEO of Hope Hospice.
[2]	Director.
[3]	Officer.
[4]	Family of Officer/Director

RELATED PARTY TRANSACTIONS (D61

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jun. 27, 2013	Dec. 31, 2016	Dec. 31, 2015
Number of shares cancelled	2,504,249
Number of shares issued		$ 22,341,156
AFH Advisory [Member]
Gain on derecognition of amounts due to related party			$ 394,446
Targeted Medical Pharma Inc [Member]
Number of shares issued			$ 150,000

GEOGRAPHIC INFORMATION (Details

GEOGRAPHIC INFORMATION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Japan [Member]
Company revenue earned from countries outside of the U.S.
Revenue	$ 160,543	$ 194,142
Percentage of revenue (in percent)	35.00%	33.00%
Taiwan [Member]
Company revenue earned from countries outside of the U.S.
Revenue	$ 220,397	$ 277,637
Percentage of revenue (in percent)	48.00%	47.00%
South Korea [Member]
Company revenue earned from countries outside of the U.S.
Revenue		$ 39,660
Percentage of revenue (in percent)	0.00%	7.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)		Jan. 02, 2017	Dec. 31, 2016	Aug. 26, 2016
Principal Amounts			$ 16,212,313
Convertible Notes Payable [Member]
Conversion Price				$ 3.50
Subsequent Event [Member]
Principal Amounts		$ 2,452,163
Subsequent Event [Member] | Convertible Notes Payable [Member]
Principal Amounts	[1]	$ 504,312
Annual Interest Rate	[1]	10.00%
Term of Notes	[1]	Due on Demand to 2 Years
Conversion Price	[1]	$ 3.60
Subsequent Event [Member] | Convertible Notes Payable [Member]
Principal Amounts	[1]	$ 1,130,536
Annual Interest Rate	[1]	10.00%
Term of Notes	[1]	6 Months to 2 Years
Conversion Price	[1]	$ 3.50
Subsequent Event [Member] | Convertible Notes Payable [Member]
Principal Amounts		$ 200,000
Annual Interest Rate		10.00%
Term of Notes	[1]	Due on Demand to 6 Months
Conversion Price		$ 7.60
Subsequent Event [Member] | Promissory Notes Payable [Member]
Principal Amounts	[1],[2]	$ 605,315
Annual Interest Rate	[1],[2]	11.00%
Term of Notes	[1],[2]	Due on Demand
Subsequent Event [Member] | Promissory Notes - Related Party [Member]
Principal Amounts	[1]	$ 12,000
Annual Interest Rate	[1]	10.00%
Term of Notes	[1]	Due on Demand
Conversion Price	[1]
[1]	Refinancings of prior notes already outstanding.
[2]	Principal amount of note is JPY68,320,000 which was converted into US dollars using an exchange rate of 0.008860 as of February 17, 2017.

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		Jan. 16, 2017	Jan. 02, 2017	Dec. 31, 2016	May 01, 2017	Mar. 28, 2017	Mar. 06, 2017	Feb. 17, 2017	Feb. 06, 2017
Principal amounts				$ 16,212,313
Proceeds from issuance of common stock				$ 22,341,156
Subsequent Event [Member]
Principal amounts			$ 2,452,163
Number of shares issued			13,000
Proceeds from issuance of common stock			$ 98,000
Subsequent Event [Member] | Letter of intent ("LOI") [Member] | Generex Biotechnology Corporation ("Generex") [Member]
Total consideration		$ 225,000,000
Cash consideration		$ 10,000,000
Number of shares issued		215,000,000
Business acquisition, share price		$ 3.80
Security deposit		$ 500,000			$ 6,000,000	$ 3,000,000	$ 500,000		$ 1,500,000
Subsequent Event [Member] | Letter of intent ("LOI") [Member] | Generex Biotechnology Corporation ("Generex") [Member] | Restricted Stock [Member]
Number of shares issued		24,414,063
Subsequent Event [Member] | Promissory Notes Payable [Member]
Principal amounts	[1],[2]		605,315
Exchange rate								$ 0.008860
Subsequent Event [Member] | Promissory Notes Payable [Member] | Japanese Yen [Member]
Principal amounts			$ 68,320,000
[1]	Principal amount of note is JPY68,320,000 which was converted into US dollars using an exchange rate of 0.008860 as of February 17, 2017.
[2]	Refinancings of prior notes already outstanding.